Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:sirolimus
go back to main search page
Accession:CHEBI:9168 term browser browse the term
Definition:A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.
Synonyms:exact_synonym: (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
 related_synonym: (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone;   Antibiotic AY 22989;   Formula=C51H79NO13;   InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1;   InChIKey=QFJCIRLUMZQUOT-HPLJOQBZSA-N;   Rapamune;   SMILES=[H][C@]1(CC[C@@H](O)[C@@H](C1)OC)C[C@@H](C)[C@]1([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@H](C[C@]2([H])CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@@]2([H])C(=O)O1)OC;   rapamycin;   sirolimusum
 alt_id: CHEBI:45276;   CHEBI:67812
 xref: CAS:53123-88-9;   DrugBank:DB00877;   Drug_Central:2446;   HMDB:HMDB0015015;   KEGG:C07909;   KEGG:D00753;   KNApSAcK:C00018055;   LIPID_MAPS_instance:LMPK06000003
 xref_mesh: MESH:D020123
 xref: PDBeChem:RAP;   PMID:22960739;   PMID:22981852;   PMID:22984623;   Reaxys:5848501;   Wikipedia:Rapamycin


show annotations for term's descendants           Sort by:
 
sirolimus term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G A2m alpha-2-macroglobulin increases expression EXP Sirolimus results in increased expression of A2M mRNA CTD PMID:21865292 NCBI chr 4:154,309,426...154,359,138
Ensembl chr 4:154,309,426...154,359,137
JBrowse link
G Abca1 ATP binding cassette subfamily A member 1 multiple interactions
increases expression
ISO
EXP
[Sirolimus co-treated with Cyclosporine] results in decreased expression of ABCA1 protein; [Sirolimus co-treated with Tacrolimus] results in increased expression of ABCA1 protein
Sirolimus results in increased expression of ABCA1 mRNA
CTD PMID:17016853, PMID:21865292 NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A affects metabolic processing
affects transport
ISO ABCB1 protein affects the metabolism of Sirolimus
ABCB1 protein affects the transport of Sirolimus
CTD PMID:15707415, PMID:15760093, PMID:15964407 NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 decreases expression EXP Sirolimus results in decreased expression of ABCC2 mRNA CTD PMID:11589784 NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
JBrowse link
G Abcc8 ATP binding cassette subfamily C member 8 decreases expression EXP Sirolimus results in decreased expression of ABCC8 mRNA CTD PMID:21865292 NCBI chr 1:102,110,708...102,191,287
Ensembl chr 1:102,110,708...102,191,287
JBrowse link
G Acadl acyl-CoA dehydrogenase, long chain multiple interactions EXP Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of ACADL mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of ACADL mRNA]] CTD PMID:25045214 NCBI chr 9:73,833,368...73,871,857
Ensembl chr 9:73,833,388...73,871,888
JBrowse link
G Acadm acyl-CoA dehydrogenase medium chain multiple interactions EXP Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of ACADM mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of ACADM mRNA]] CTD PMID:25045214 NCBI chr 2:260,124,418...260,148,589
Ensembl chr 2:260,124,418...260,148,589
JBrowse link
G Ace2 angiotensin I converting enzyme 2 decreases expression EXP Sirolimus results in decreased expression of ACE2 mRNA CTD PMID:21865292 NCBI chr  X:32,050,734...32,095,860
Ensembl chr  X:32,049,931...32,096,016
JBrowse link
G Acer2 alkaline ceramidase 2 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in decreased expression of ACER2 mRNA] CTD PMID:21245298 NCBI chr 5:105,230,540...105,279,732
Ensembl chr 5:105,230,580...105,279,731
JBrowse link
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO [Sirolimus co-treated with IGF1 protein] results in increased expression of ACTA2 protein CTD PMID:17908691 NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
JBrowse link
G Actb actin, beta increases expression
multiple interactions
ISO Sirolimus results in increased expression of ACTB mRNA
[Sirolimus binds to FKBP1A protein] which results in increased expression of ACTB mRNA
CTD PMID:7503980 NCBI chr12:13,715,843...13,718,813
Ensembl chr12:13,715,843...13,718,841
JBrowse link
G Agt angiotensinogen multiple interactions EXP Sirolimus inhibits the reaction [AGT protein affects the localization of Calcium] CTD PMID:21613610 NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
JBrowse link
G Aifm1 apoptosis inducing factor, mitochondria associated 1 decreases expression
multiple interactions
EXP
ISO
Sirolimus results in decreased expression of AIFM1 protein
[7-hydroxystaurosporine co-treated with Sirolimus] affects the localization of AIFM1 protein; Boc-D-FMK inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] affects the localization of AIFM1 protein]
CTD PMID:15767555, PMID:16497721 NCBI chr  X:135,304,063...135,343,062
Ensembl chr  X:135,304,066...135,343,087
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
affects phosphorylation
increases phosphorylation
decreases phosphorylation
ISO
EXP
[Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of BCL2L11 protein; [Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of CDKN1B protein; [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of AKT1 protein; [Sirolimus co-treated with Arsenic Trioxide] results in decreased phosphorylation of AKT1 protein; Arsenic Trioxide inhibits the reaction [Sirolimus results in increased phosphorylation of AKT1 protein]; Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]; Cisplatin inhibits the reaction [Sirolimus results in increased phosphorylation of AKT1 protein]; Resveratrol inhibits the reaction [Sirolimus results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [Estradiol results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [Tretinoin results in increased phosphorylation of AKT1 protein]
Sirolimus affects the phosphorylation of AKT1 protein
resveratrol inhibits the reaction [Sirolimus results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [IGF1 protein inhibits the reaction [Isoflurane results in decreased phosphorylation of AKT1 protein]]
[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein; Sirolimus results in increased phosphorylation of AKT1 protein
Sirolimus results in decreased phosphorylation of AKT1 protein
[Sirolimus co-treated with Resveratrol] promotes the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [[Cadmium Chloride co-treated with TGFB1 protein] results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [AKT1 protein mutant form results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [Resveratrol results in decreased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [TSC1 gene mutant form results in decreased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1 protein]
CTD PMID:15806154, PMID:18495876, PMID:18622747, PMID:19176369, PMID:21092744, PMID:21976531, PMID:23000059, PMID:24299490, PMID:24304514, PMID:24392034, PMID:25597859, PMID:25758096, PMID:26282490, PMID:26369790, PMID:28108221, PMID:28342888, PMID:30905858, PMID:31499194 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Akt1s1 AKT1 substrate 1 multiple interactions ISO
EXP
[Sirolimus co-treated with resveratrol] results in decreased phosphorylation of AKT1S1 protein; resveratrol inhibits the reaction [Sirolimus inhibits the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1S1 protein]]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1S1 protein]
[resveratrol co-treated with Sirolimus] results in decreased phosphorylation of AKT1S1 protein
CTD PMID:24304514 NCBI chr 1:100,845,443...100,851,961
Ensembl chr 1:100,845,563...100,851,960
JBrowse link
G Akt2 AKT serine/threonine kinase 2 multiple interactions ISO [Sirolimus results in increased activity of AKT2 protein] which results in increased expression of CALD1 protein; [Sirolimus results in increased activity of AKT2 protein] which results in increased expression of MYH11 protein; Sirolimus results in increased phosphorylation of and results in increased activity of AKT2 protein CTD PMID:17908691 NCBI chr 1:84,400,939...84,451,223
Ensembl chr 1:84,411,726...84,450,162
JBrowse link
G Angptl6 angiopoietin-like 6 increases expression EXP Sirolimus results in increased expression of ANGPTL6 mRNA CTD PMID:21865292 NCBI chr 8:21,895,523...21,902,002
Ensembl chr 8:21,895,524...21,901,829
JBrowse link
G Aopep aminopeptidase O multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of AOPEP mRNA] CTD PMID:21245298 NCBI chr17:507,389...825,062
Ensembl chr17:507,377...821,582
JBrowse link
G Apod apolipoprotein D affects localization ISO Sirolimus affects the localization of APOD protein CTD PMID:28182653 NCBI chr11:72,705,204...72,726,263
Ensembl chr11:72,705,129...72,726,301
JBrowse link
G App amyloid beta precursor protein decreases expression
increases expression
ISO Sirolimus results in decreased expression of APP protein modified form
Sirolimus results in increased expression of APP protein modified form
CTD PMID:20542014 NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
JBrowse link
G Aqp2 aquaporin 2 multiple interactions
decreases expression
EXP rosiglitazone inhibits the reaction [Sirolimus results in decreased expression of AQP2 protein] CTD PMID:19656910 NCBI chr 7:141,237,802...141,242,837
Ensembl chr 7:141,237,768...141,245,165
JBrowse link
G Ar androgen receptor multiple interactions
increases expression
increases activity
ISO [Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein]] which results in increased activity of AR protein; bicalutamide inhibits the reaction [Sirolimus results in increased activity of AR protein]; RPTOR protein inhibits the reaction [Sirolimus results in increased activity of AR protein]; Sirolimus affects the reaction [Testosterone results in increased expression of AR protein]; Sirolimus promotes the reaction [Dihydrotestosterone affects the expression of AR protein]
Sirolimus results in increased expression of AR protein
CTD PMID:18776922, PMID:21036700 NCBI chr  X:67,656,253...67,828,998
Ensembl chr  X:67,656,253...67,829,026
JBrowse link
G Asns asparagine synthetase (glutamine-hydrolyzing) multiple interactions ISO Sirolimus inhibits the reaction [IL2 protein results in increased expression of ASNS mRNA] CTD PMID:11355896 NCBI chr 4:33,742,876...33,761,106
Ensembl chr 4:33,743,364...33,761,163
JBrowse link
G Atf3 activating transcription factor 3 multiple interactions ISO [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of ATF3 mRNA CTD PMID:25307878 NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
JBrowse link
G Atf4 activating transcription factor 4 multiple interactions ISO
EXP
Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of ATF4]
Sirolimus inhibits the reaction [cadmium acetate results in increased expression of ATF4 protein]
CTD PMID:24057571, PMID:29870746 NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
JBrowse link
G Atg4a autophagy related 4A, cysteine peptidase increases expression ISO Sirolimus results in increased expression of ATG4A mRNA CTD PMID:21681844 NCBI chr  X:112,328,907...112,403,157 JBrowse link
G Atg4b autophagy related 4B, cysteine peptidase increases expression ISO Sirolimus results in increased expression of ATG4B mRNA CTD PMID:21681844 NCBI chr 9:100,888,457...100,920,123
Ensembl chr 9:100,888,501...100,918,637
JBrowse link
G Atg5 autophagy related 5 multiple interactions
increases expression
ISO
EXP
[Sirolimus co-treated with TNF protein] results in increased expression of ATG5 mRNA; ATG5 protein affects the reaction [Sirolimus inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein]]
Sirolimus results in increased expression of ATG5 protein
Sirolimus results in increased expression of ATG5 mRNA; Sirolimus results in increased expression of ATG5 protein
[Sirolimus co-treated with cadmium acetate] results in increased expression of ATG5 mRNA; Sirolimus inhibits the reaction [Epirubicin results in decreased expression of ATG5 protein]; Sirolimus promotes the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in decreased expression of ATG5 protein]]
CTD PMID:19682553, PMID:29128638, PMID:29505745, PMID:29870746, PMID:30338810, PMID:30611790, PMID:31676321 NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
JBrowse link
G Atg7 autophagy related 7 multiple interactions ISO [Sirolimus co-treated with TNF protein] results in increased expression of ATG7 mRNA CTD PMID:31676321 NCBI chr 4:146,570,113...146,777,093
Ensembl chr 4:146,598,413...146,777,124
JBrowse link
G Aurkb aurora kinase B multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of AURKB mRNA CTD PMID:19016759 NCBI chr10:55,625,860...55,632,399
Ensembl chr10:55,626,741...55,634,991
JBrowse link
G Bad BCL2-associated agonist of cell death multiple interactions ISO Sirolimus inhibits the reaction [IL2 protein results in increased expression of BAD mRNA] CTD PMID:11355896 NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
JBrowse link
G Bax BCL2 associated X, apoptosis regulator affects localization
increases expression
multiple interactions
ISO Sirolimus affects the localization of BAX protein
Sirolimus results in increased expression of BAX mRNA; Sirolimus results in increased expression of BAX protein
[Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BAX mRNA; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BAX protein
[Curcumin co-treated with Sirolimus] results in increased expression of BAX; Sirolimus inhibits the reaction [rebamipide results in decreased expression of BAX protein]
CTD PMID:11602639, PMID:15782132, PMID:19373661, PMID:19922502, PMID:29054700, PMID:30905858 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bbc3 Bcl-2 binding component 3 multiple interactions ISO [[Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein] which results in increased expression of BBC3 protein; Sirolimus promotes the reaction [TP53 protein results in increased expression of BBC3 protein] CTD PMID:19560264, PMID:20686837 NCBI chr 1:78,261,491...78,267,802 JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
affects expression
decreases expression
ISO
EXP
[Curcumin co-treated with Sirolimus] results in decreased expression of BCL2; Sirolimus inhibits the reaction [Doxorubicin results in increased expression of BCL2 protein]; Sirolimus inhibits the reaction [rebamipide results in increased expression of BCL2 protein]; Sirolimus promotes the reaction [Ethanol results in increased expression of BCL2 protein]
Sirolimus affects the expression of BCL2 protein
Sirolimus inhibits the reaction [lactacystin results in decreased expression of BCL2 protein]
[Sirolimus co-treated with IL2 protein] results in increased expression of BCL2 mRNA
Sirolimus results in decreased expression of BCL2 mRNA; Sirolimus results in decreased expression of BCL2 protein
CTD PMID:11355896, PMID:15571967, PMID:18640276, PMID:19373661, PMID:19764996, PMID:19815708, PMID:21410490, PMID:29054700, PMID:30905858 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions
increases expression
decreases expression
ISO [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of BCL2L1 protein; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2L1 protein]; Sirolimus inhibits the reaction [rebamipide results in increased expression of BCL2L1 protein]
Sirolimus results in increased expression of BCL2L1 mRNA; Sirolimus results in increased expression of BCL2L1 protein
Sirolimus results in decreased expression of BCL2L1 mRNA; Sirolimus results in decreased expression of BCL2L1 protein
[Sirolimus co-treated with IL2 protein] results in increased expression of BCL2L1 mRNA; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2L1 protein]
CTD PMID:11355896, PMID:15767555, PMID:15782132, PMID:18097008, PMID:18789402, PMID:19922502, PMID:21681844, PMID:29054700 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Bcl2l11 BCL2 like 11 multiple interactions
decreases expression
increases expression
ISO [Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of BCL2L11 protein; Sirolimus inhibits the reaction [rebamipide results in decreased expression of BCL2L11 protein]; Sirolimus promotes the reaction [Cisplatin results in increased expression of BCL2L11 mRNA]
Sirolimus results in decreased expression of BCL2L11 protein
Sirolimus results in increased expression of BCL2L11 protein
CTD PMID:18097008, PMID:21092744, PMID:29054700 NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
JBrowse link
G Bdnf brain-derived neurotrophic factor multiple interactions ISO Sirolimus inhibits the reaction [BDNF protein results in increased expression of PPP1R1B mRNA]; Sirolimus inhibits the reaction [BDNF protein results in increased expression of PPP1R1B protein] CTD PMID:17209049 NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
JBrowse link
G Becn1 beclin 1 multiple interactions
increases expression
ISO
EXP
[Sirolimus co-treated with TNF protein] results in increased expression of BECN1 protein; Sirolimus inhibits the reaction [Ethanol results in increased degradation of BECN1 protein]; Sirolimus inhibits the reaction [Paraquat results in decreased expression of BECN1 protein]; Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased expression of BECN1 protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of BECN1 protein]; Sirolimus promotes the reaction [Caffeine results in increased expression of BECN1 protein]; Sirolimus promotes the reaction [tris(1,3-dichloro-2-propyl)phosphate results in increased expression of BECN1 protein]
[Sirolimus co-treated with cadmium acetate] results in increased expression of BECN1 mRNA; Sirolimus inhibits the reaction [Epirubicin results in decreased expression of BECN1 protein]; Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased expression of BECN1 protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of BECN1 protein]; Sirolimus promotes the reaction [T-2 Toxin results in increased expression of BECN1 mRNA]
Sirolimus results in increased expression of BECN1 protein
Sirolimus results in increased expression of BECN1 mRNA; Sirolimus results in increased expression of BECN1 protein
CTD PMID:20358864, PMID:21410490, PMID:26648565, PMID:26825372, PMID:27107786, PMID:28025121, PMID:28888487, PMID:29505745, PMID:29518472, PMID:29870746, PMID:30555576, PMID:30611790, PMID:30629952, PMID:30905858, PMID:31676321, PMID:32306690, PMID:32430275, PMID:32645460 NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
JBrowse link
G Bglap bone gamma-carboxyglutamate protein multiple interactions ISO Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA] CTD PMID:23111315 NCBI chr 2:187,741,770...187,748,445
Ensembl chr 2:187,741,770...187,742,747
JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions
increases expression
decreases expression
ISO [7-hydroxystaurosporine co-treated with Sirolimus] results in increased cleavage of BID protein
Sirolimus results in increased expression of BID mRNA; Sirolimus results in increased expression of BID protein
Sirolimus results in decreased expression of BID protein
[Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BID mRNA; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BID protein
CTD PMID:15767555, PMID:18097008, PMID:19922502 NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
JBrowse link
G Birc2 baculoviral IAP repeat-containing 2 multiple interactions
increases expression
affects localization
ISO
EXP
Sirolimus inhibits the reaction [Doxorubicin results in increased expression of BIRC2 protein]
Sirolimus results in increased expression of BIRC2 protein
Sirolimus affects the localization of BIRC2 protein
CTD PMID:15571967, PMID:21357504 NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions
decreases expression
ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of BIRC5 mRNA; Sirolimus inhibits the reaction [N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide results in increased expression of and affects the localization of BIRC5 protein]; Sirolimus promotes the reaction [Tamoxifen results in decreased expression of BIRC5 protein]
Sirolimus results in decreased expression of BIRC5 protein
CTD PMID:19016759, PMID:19931998, PMID:21601561, PMID:24444656 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
JBrowse link
G Bmp2 bone morphogenetic protein 2 multiple interactions ISO Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA] CTD PMID:23111315 NCBI chr 3:126,335,963...126,346,771
Ensembl chr 3:126,335,863...126,346,318
JBrowse link
G Bnip3 BCL2 interacting protein 3 multiple interactions ISO Sirolimus inhibits the reaction [IL2 protein results in increased expression of BNIP3 mRNA] CTD PMID:11355896 NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
JBrowse link
G Btbd11 BTB domain containing 11 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of BTBD11 mRNA] CTD PMID:21245298 NCBI chr 7:24,041,194...24,314,418
Ensembl chr 7:24,043,126...24,313,885
JBrowse link
G Btc betacellulin multiple interactions EXP Sirolimus inhibits the reaction [BTC protein affects the localization of CDKN1A protein]; Sirolimus inhibits the reaction [BTC protein affects the localization of CDKN1B protein]; Sirolimus inhibits the reaction [BTC protein results in increased expression of CCND1 protein] CTD PMID:19105244 NCBI chr14:18,231,854...18,270,621
Ensembl chr14:18,231,860...18,272,484
JBrowse link
G Btk Bruton tyrosine kinase multiple interactions ISO Sirolimus inhibits the reaction [IL2 protein results in increased expression of BTK mRNA] CTD PMID:11355896 NCBI chr  X:105,360,922...105,390,580
Ensembl chr  X:105,360,922...105,390,580
JBrowse link
G Bub1 BUB1 mitotic checkpoint serine/threonine kinase multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of BUB1 mRNA CTD PMID:19016759 NCBI chr 3:120,373,604...120,404,910
Ensembl chr 3:120,373,604...120,404,910
JBrowse link
G Bub1b BUB1 mitotic checkpoint serine/threonine kinase B multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of BUB1B mRNA CTD PMID:19016759 NCBI chr 3:110,367,949...110,420,471
Ensembl chr 3:110,367,939...110,420,458
JBrowse link
G C1qa complement C1q A chain decreases expression EXP Sirolimus results in decreased expression of C1QA mRNA CTD PMID:21865292 NCBI chr 5:155,261,254...155,264,101
Ensembl chr 5:155,261,250...155,264,143
JBrowse link
G C1qc complement C1q C chain decreases expression EXP Sirolimus results in decreased expression of C1QC mRNA CTD PMID:21865292 NCBI chr 5:155,255,013...155,258,631
Ensembl chr 5:155,255,005...155,258,392
JBrowse link
G C3 complement C3 decreases expression EXP Sirolimus results in decreased expression of C3 mRNA CTD PMID:21865292 NCBI chr 9:9,721,137...9,747,084
Ensembl chr 9:9,721,105...9,747,167
JBrowse link
G Cald1 caldesmon 1 multiple interactions
increases expression
ISO [Sirolimus co-treated with IGF1 protein] results in increased expression of CALD1 protein; [Sirolimus results in increased activity of AKT2 protein] which results in increased expression of CALD1 protein
Sirolimus results in increased expression of CALD1 protein
CTD PMID:17908691 NCBI chr 4:62,103,948...62,291,375
Ensembl chr 4:62,220,736...62,291,489
JBrowse link
G Camk2a calcium/calmodulin-dependent protein kinase II alpha multiple interactions EXP Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of CAMK2A protein] CTD PMID:21933187 NCBI chr18:56,193,978...56,295,869
Ensembl chr18:56,193,978...56,295,869
JBrowse link
G Capn1 calpain 1 decreases activity EXP Sirolimus results in decreased activity of CAPN1 protein CTD PMID:21357504 NCBI chr 1:221,346,081...221,370,965
Ensembl chr 1:221,346,066...221,370,322
JBrowse link
G Casp1 caspase 1 multiple interactions ISO
EXP
Sirolimus inhibits the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]
Sirolimus inhibits the reaction [[Zearalenone co-treated with Lipopolysaccharides] results in increased expression of CASP1 protein modified form]
CTD PMID:30205151, PMID:31586597 NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
JBrowse link
G Casp12 caspase 12 decreases cleavage
multiple interactions
ISO
EXP
Sirolimus results in decreased cleavage of CASP12 protein
Sirolimus inhibits the reaction [cadmium acetate results in increased expression of CASP12 protein]
CTD PMID:20511674, PMID:29870746 NCBI chr 8:2,658,892...2,686,160
Ensembl chr 8:2,659,865...2,686,160
JBrowse link
G Casp2 caspase 2 multiple interactions ISO [Boc-D-FMK co-treated with Sirolimus] results in increased cleavage of CASP2 protein; Boc-D-FMK inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP2 protein] CTD PMID:15767555 NCBI chr 4:71,652,358...71,670,228
Ensembl chr 4:71,652,354...71,670,239
JBrowse link
G Casp3 caspase 3 multiple interactions
increases expression
decreases activity
increases activity
increases cleavage
ISO
EXP
[7-hydroxystaurosporine co-treated with Sirolimus] results in increased cleavage of CASP3 protein; [Curcumin co-treated with Sirolimus] results in increased activity of CASP3 protein; [S 1 (combination) co-treated with Sirolimus] results in increased expression of CASP3 protein; [Sirolimus co-treated with Paclitaxel] results in increased cleavage of CASP3 protein; Boc-D-FMK inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP3 protein]; Fluorouracil promotes the reaction [Sirolimus results in increased expression of CASP3 mRNA]; pyrazolanthrone inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [chromium hexavalent ion results in increased activity of CASP3 protein]; Sirolimus inhibits the reaction [Ethanol results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [Rotenone results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [TNF protein results in increased cleavage of CASP3 protein]; Sirolimus promotes the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Sirolimus promotes the reaction [Doxorubicin results in increased activity of CASP3 protein]; Sirolimus promotes the reaction [Fluorouracil results in increased expression of CASP3 mRNA]
Sirolimus results in increased expression of CASP3 protein modified form
Sirolimus inhibits the reaction [Cadmium Chloride results in increased activity of CASP3 protein]; Sirolimus inhibits the reaction [TGFB1 protein inhibits the reaction [Cadmium Chloride results in increased expression of CASP3 protein]]; Sirolimus promotes the reaction [Cadmium results in increased cleavage of CASP3 protein]
Sirolimus results in decreased activity of CASP3 protein
[Sirolimus co-treated with Resveratrol] results in increased cleavage of CASP3 protein; Sirolimus inhibits the reaction [decamethrin results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [Staurosporine results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [T-2 Toxin results in increased expression of CASP3 protein modified form]; Sirolimus promotes the reaction [decamethrin results in increased cleavage of CASP3 protein]; Sirolimus results in decreased cleavage of and results in decreased activity of CASP3 protein
Sirolimus results in increased expression of CASP3 mRNA; Sirolimus results in increased expression of CASP3 protein
Sirolimus results in increased activity of CASP3 protein
Sirolimus results in increased cleavage of CASP3 protein
CTD PMID:14502240, PMID:15571967, PMID:15753396, PMID:15767555, PMID:15782132, PMID:15878982, PMID:16497721, PMID:18058806, PMID:18097008, PMID:19373661, PMID:19682553, PMID:19764996, PMID:20031680, PMID:20358864, PMID:21357504, PMID:21410490, PMID:21681844, PMID:24299490, PMID:24304514, PMID:26588882, PMID:26825372, PMID:28342888, PMID:29111403, PMID:30030080, PMID:30236763, PMID:30629952, PMID:31676321 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp7 caspase 7 multiple interactions
decreases activity
ISO
EXP
[Curcumin co-treated with Sirolimus] results in increased activity of CASP7 protein; [Sirolimus co-treated with Paclitaxel] results in increased cleavage of CASP7 protein
Sirolimus results in decreased activity of CASP7 protein
CTD PMID:15753396, PMID:19373661, PMID:20031680 NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
JBrowse link
G Casp8 caspase 8 multiple interactions
increases cleavage
ISO [7-hydroxystaurosporine co-treated with Sirolimus] results in increased cleavage of CASP8 protein; [tanespimycin co-treated with Sirolimus] results in increased cleavage of CASP8 protein; pyrazolanthrone inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP8 protein]; Sirolimus promotes the reaction [Cisplatin results in increased cleavage of CASP8 protein]
Sirolimus inhibits the reaction [TGFB1 protein inhibits the reaction [Cadmium Chloride results in increased expression of CASP8 protein]]
Sirolimus results in increased cleavage of CASP8 protein
CTD PMID:15767555, PMID:17121904, PMID:18058806, PMID:25307878, PMID:28342888 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Casp9 caspase 9 multiple interactions
decreases activity
ISO
EXP
[7-hydroxystaurosporine co-treated with Sirolimus] results in increased cleavage of CASP9 protein; [Curcumin co-treated with Sirolimus] results in increased activity of CASP9 protein; [Sirolimus co-treated with Cisplatin] results in increased activity of CASP9 protein; [Sirolimus co-treated with Paclitaxel] results in increased cleavage of CASP9 protein; [tanespimycin co-treated with Sirolimus] results in increased cleavage of CASP9 protein; Sirolimus promotes the reaction [Cisplatin results in increased cleavage of CASP9 protein]
Sirolimus inhibits the reaction [TGFB1 protein inhibits the reaction [Cadmium Chloride results in increased expression of CASP9 protein]]
Sirolimus inhibits the reaction [Staurosporine results in increased cleavage of CASP9 protein]
Sirolimus results in decreased activity of CASP9 protein
CTD PMID:15753396, PMID:15767555, PMID:16497721, PMID:17121904, PMID:18058806, PMID:18097008, PMID:19373661, PMID:20138251, PMID:28342888 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Cat catalase increases expression ISO Sirolimus results in increased expression of CAT protein CTD PMID:30905858 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Cav3 caveolin 3 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of CAV3 mRNA] CTD PMID:21245298 NCBI chr 4:144,382,945...144,398,919
Ensembl chr 4:144,382,945...144,398,917
JBrowse link
G Ccn2 cellular communication network factor 2 increases expression EXP Sirolimus results in increased expression of CCN2 mRNA CTD PMID:21865292 NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
JBrowse link
G Ccna2 cyclin A2 multiple interactions
decreases expression
ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of CCNA2 mRNA
Sirolimus results in decreased expression of CCNA2 protein
Sirolimus results in decreased expression of CCNA2; Sirolimus results in decreased expression of CCNA2 protein
CTD PMID:7503980, PMID:8419408, PMID:19016759, PMID:19505958 NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
JBrowse link
G Ccnb2 cyclin B2 multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of CCNB2 mRNA CTD PMID:19016759 NCBI chr 8:76,847,972...76,861,165 JBrowse link
G Ccnd1 cyclin D1 multiple interactions
decreases expression
increases expression
increases degradation
ISO
EXP
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Sirolimus results in increased expression of CCND1 protein]; [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with Sirolimus] results in decreased expression of CCND1; [3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of CCND1 protein; [Lithium Chloride results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [SB 216763 results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [Sirolimus co-treated with Letrozole] results in decreased expression of CCND1 protein; [Sirolimus co-treated with tanespimycin] results in decreased expression of CCND1 protein; [Sirolimus results in increased activity of GSK3B protein] which results in increased phosphorylation of and results in increased degradation of CCND1 protein
Sirolimus inhibits the reaction [BTC protein results in increased expression of CCND1 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased expression of CCND1 protein]
Sirolimus results in increased degradation of CCND1 protein
CTD PMID:7532117, PMID:15753396, PMID:15767555, PMID:17121904, PMID:19105244, PMID:19505958, PMID:19661225, PMID:20054642, PMID:23006739 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Ccnd2 cyclin D2 multiple interactions
decreases expression
ISO
EXP
[Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased expression of CCND2 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of CCND2 mRNA]
Sirolimus results in decreased expression of CCND2 protein
Sirolimus inhibits the reaction [FSHB protein results in increased expression of CCND2 mRNA]
CTD PMID:15070696, PMID:15778701, PMID:17510244 NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
JBrowse link
G Ccnd3 cyclin D3 multiple interactions
decreases expression
decreases stability
ISO [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased expression of CCND3 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of CCND3 mRNA]
Sirolimus results in decreased expression of CCND3 mRNA; Sirolimus results in decreased expression of CCND3 protein
Sirolimus inhibits the reaction [KITL protein results in increased expression of CCND3 protein]
Sirolimus results in decreased stability of CCND3 mRNA
CTD PMID:10849422, PMID:12393642, PMID:15070696, PMID:15778701, PMID:15882288 NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943
JBrowse link
G Ccne2 cyclin E2 multiple interactions ISO [Fulvestrant co-treated with Sirolimus] results in decreased expression of CCNE2 mRNA; Sirolimus inhibits the reaction [PIK3CA protein modified form results in increased expression of CCNE2 mRNA] CTD PMID:19016759, PMID:27542212 NCBI chr 5:24,434,077...24,446,406
Ensembl chr 5:24,434,872...24,446,406
JBrowse link
G Ccng2 cyclin G2 multiple interactions
increases expression
ISO [cotylenin A co-treated with Sirolimus] results in increased expression of CCNG2 mRNA; Sirolimus inhibits the reaction [PIK3CA protein modified form results in decreased expression of CCNG2 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of CCNG2 mRNA]
Sirolimus results in increased expression of CCNG2 mRNA
CTD PMID:18754885, PMID:21245298, PMID:24356939, PMID:27542212 NCBI chr14:16,267,572...16,276,068
Ensembl chr14:16,267,573...16,276,068
JBrowse link
G Ccni cyclin I multiple interactions ISO Sirolimus inhibits the reaction [IL2 protein results in decreased expression of CCNI mRNA] CTD PMID:11355896 NCBI chr14:16,341,510...16,364,326
Ensembl chr14:16,341,536...16,364,326
JBrowse link
G Cd36 CD36 molecule affects expression
multiple interactions
ISO Sirolimus affects the expression of CD36 protein
Sirolimus inhibits the reaction [Oxygen deficiency results in increased expression of CD36 mRNA]
CTD PMID:17016853, PMID:19640849 NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
JBrowse link
G Cd38 CD38 molecule multiple interactions ISO CD38 gene mutant form promotes the reaction [Sirolimus results in increased expression of MAP1LC3B protein]; CD38 mutant form inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein] CTD PMID:24238063, PMID:24445604 NCBI chr14:71,714,768...71,754,990
Ensembl chr14:71,715,269...71,754,672
JBrowse link
G Cd68 Cd68 molecule decreases expression ISO
EXP
Sirolimus results in decreased expression of CD68 mRNA CTD PMID:17016853, PMID:21865292 NCBI chr10:56,268,726...56,270,605
Ensembl chr10:56,268,720...56,270,640
JBrowse link
G Cd80 Cd80 molecule decreases expression ISO Sirolimus results in decreased expression of CD80 protein CTD PMID:12531798 NCBI chr11:64,815,201...64,855,293
Ensembl chr11:64,827,635...64,855,353
JBrowse link
G Cd84 CD84 molecule increases expression ISO Sirolimus results in increased expression of CD84 mRNA CTD PMID:24356939 NCBI chr13:90,241,369...90,283,625
Ensembl chr13:90,244,681...90,277,865
JBrowse link
G Cd86 CD86 molecule decreases expression ISO Sirolimus results in decreased expression of CD86 protein CTD PMID:12531798 NCBI chr11:67,060,305...67,117,990
Ensembl chr11:67,082,193...67,118,795
JBrowse link
G Cdc20 cell division cycle 20 multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of CDC20 mRNA CTD PMID:19016759 NCBI chr 5:137,260,728...137,264,931
Ensembl chr 5:137,260,739...137,265,015
JBrowse link
G Cdh1 cadherin 1 increases expression
multiple interactions
ISO
EXP
Sirolimus results in increased expression of CDH1 protein
NFE2L2 protein promotes the reaction [Sirolimus inhibits the reaction [Paraquat results in decreased expression of CDH1 protein]]; Sirolimus inhibits the reaction [Paraquat results in decreased expression of CDH1 mRNA]; Sirolimus inhibits the reaction [Paraquat results in decreased expression of CDH1 protein]; Sirolimus promotes the reaction [Dibutyl Phthalate results in decreased expression of CDH1 mRNA]; Sirolimus promotes the reaction [Dibutyl Phthalate results in decreased expression of CDH1 protein]
Sirolimus inhibits the reaction [sodium arsenite results in decreased expression of CDH1 protein]
CTD PMID:28624451, PMID:28888487, PMID:30053495 NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
JBrowse link
G Cdh2 cadherin 2 multiple interactions EXP Sirolimus promotes the reaction [Dibutyl Phthalate results in increased expression of CDH2 mRNA]; Sirolimus promotes the reaction [Dibutyl Phthalate results in increased expression of CDH2 protein] CTD PMID:30053495 NCBI chr18:8,146,971...8,366,037
Ensembl chr18:8,146,971...8,360,684
JBrowse link
G Cdk1 cyclin-dependent kinase 1 multiple interactions
decreases activity
decreases expression
ISO
EXP
[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of CDK1 mRNA; [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of CDK1 protein; [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of CDK1 protein; [fulvestrant co-treated with Sirolimus] results in decreased expression of CDK1 mRNA
Sirolimus results in decreased activity of CDK1 protein
Sirolimus results in decreased expression of CDK1 mRNA; Sirolimus results in decreased expression of CDK1 protein
Sirolimus inhibits the reaction [IL2 protein results in increased expression of CDK1 mRNA]
CTD PMID:7503980, PMID:7532117, PMID:8419408, PMID:11355896, PMID:15767555, PMID:19016759, PMID:19223503, PMID:19922502 NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
JBrowse link
G Cdk2 cyclin dependent kinase 2 multiple interactions
decreases activity
ISO
EXP
[Sirolimus co-treated with TGFB1 protein] affects the localization of CDK2 protein; [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1A protein binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL1 protein] which binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL2 protein] which binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1A protein]; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein]; [TGFB1 protein co-treated with Sirolimus] results in decreased activity of CDK2 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of CDK2 protein
[Sirolimus co-treated with TGFB1 protein] affects the localization of CDK2 protein; [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1B protein binds to CDK2 protein]; [Sirolimus co-treated with TGFB1 protein] results in decreased activity of CDK2 protein; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein]
Sirolimus results in decreased activity of CDK2 protein
CTD PMID:7532117, PMID:12393642, PMID:12417722, PMID:14979923, PMID:21528311 NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
JBrowse link
G Cdk4 cyclin-dependent kinase 4 decreases expression ISO Sirolimus results in decreased expression of CDK4 protein CTD PMID:22761470 NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions
decreases expression
increases expression
ISO
EXP
[(+)-JQ1 compound co-treated with Sirolimus] results in increased expression of CDKN1A mRNA; [(+)-JQ1 compound co-treated with Sirolimus] results in increased expression of CDKN1A protein; [S 1 (combination) co-treated with Sirolimus] results in increased expression of CDKN1A protein; [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1A protein binds to CDK2 protein]; [Sirolimus co-treated with TGFB1 protein] results in increased expression of CDKN1A protein; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1A protein]; [TGFB1 protein co-treated with Sirolimus] results in increased expression of CDKN1A protein; Fluorouracil promotes the reaction [Sirolimus results in increased expression of CDKN1A mRNA]; Sirolimus inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased expression of CDKN1A protein]; Sirolimus promotes the reaction [(+)-JQ1 compound results in increased expression of CDKN1A mRNA]; Sirolimus promotes the reaction [(+)-JQ1 compound results in increased expression of CDKN1A protein]; Sirolimus promotes the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased expression of CDKN1A protein]]; Sirolimus promotes the reaction [Fluorouracil results in increased expression of CDKN1A mRNA]
Sirolimus results in decreased expression of CDKN1A protein
Sirolimus results in increased expression of CDKN1A mRNA; Sirolimus results in increased expression of CDKN1A protein
Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; Sirolimus inhibits the reaction [BTC protein affects the localization of CDKN1A protein]; Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]; Sirolimus inhibits the reaction [IGF1 protein affects the localization of CDKN1A protein]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]
CTD PMID:12417722, PMID:14979923, PMID:17700525, PMID:19105244, PMID:19764996, PMID:21528311, PMID:22561310, PMID:25307878, PMID:30555576 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions
decreases expression
increases expression
decreases degradation
ISO
EXP
[Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of CDKN1B protein; [Decitabine co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Sirolimus] results in increased expression of CDKN1B mRNA; [Sirolimus co-treated with TGFB1 protein] affects the localization of CDKN1B protein; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein]; Sirolimus promotes the reaction [Cisplatin results in increased expression of CDKN1B mRNA]
Sirolimus results in decreased expression of CDKN1B protein
Sirolimus results in increased expression of CDKN1B protein
Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]; Sirolimus inhibits the reaction [BTC protein affects the localization of CDKN1B protein]; Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]; Sirolimus inhibits the reaction [IGF1 protein affects the localization of CDKN1B protein]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]
[Sirolimus co-treated with TGFB1 protein] affects the localization of CDKN1B protein; [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1B protein binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein]
Sirolimus results in decreased degradation of CDKN1B protein
CTD PMID:12417722, PMID:12565877, PMID:14979923, PMID:15070696, PMID:16455087, PMID:18622747, PMID:19105244, PMID:21092744, PMID:22561310 NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
JBrowse link
G Cdx2 caudal type homeo box 2 increases expression ISO Sirolimus results in increased expression of CDX2 mRNA CTD PMID:21681844 NCBI chr12:9,464,026...9,470,565
Ensembl chr12:9,464,026...9,470,565
JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha decreases expression ISO Sirolimus results in decreased expression of CEBPA mRNA CTD PMID:15358118 NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
JBrowse link
G Cenpx centromere protein X increases expression ISO Sirolimus results in increased expression of CENPX mRNA CTD PMID:11355896 NCBI chr10:109,890,904...109,893,804 JBrowse link
G Cfd complement factor D decreases expression ISO Sirolimus results in decreased expression of CFD mRNA CTD PMID:15358118 NCBI chr 7:12,634,216...12,635,939
Ensembl chr 7:12,634,216...12,635,943
JBrowse link
G Chrnb3 cholinergic receptor nicotinic beta 3 subunit multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of CHRNB3 mRNA] CTD PMID:21245298 NCBI chr16:68,876,442...68,913,628
Ensembl chr16:68,875,709...68,913,628
JBrowse link
G Cidec cell death-inducing DFFA-like effector c multiple interactions ISO Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in increased expression of CIDEC mRNA] CTD PMID:31499194 NCBI chr 4:145,377,482...145,390,497
Ensembl chr 4:145,377,431...145,390,497
JBrowse link
G Cks1b CDC28 protein kinase regulatory subunit 1B decreases expression ISO Sirolimus results in decreased expression of CKS1B mRNA CTD PMID:11355896 NCBI chr 2:188,740,564...188,745,144
Ensembl chr 2:188,740,573...188,745,144
JBrowse link
G Cldn7 claudin 7 increases expression EXP Sirolimus results in increased expression of CLDN7 mRNA CTD PMID:21865292 NCBI chr10:56,576,326...56,578,632
Ensembl chr10:56,576,428...56,578,626
JBrowse link
G Clec4a3 C-type lectin domain family 4, member A3 decreases expression EXP Sirolimus results in decreased expression of CLEC4A mRNA CTD PMID:21865292 NCBI chr 4:155,913,366...155,923,079
Ensembl chr 4:155,913,366...155,923,079
JBrowse link
G Col1a1 collagen type I alpha 1 chain decreases expression EXP Sirolimus results in decreased expression of COL1A1 mRNA CTD PMID:21865292 NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
JBrowse link
G Col1a2 collagen type I alpha 2 chain multiple interactions ISO
EXP
Sirolimus inhibits the reaction [Acetaldehyde results in increased expression of COL1A2 mRNA]
Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased expression of COL1A2 mRNA]
CTD PMID:10535884, PMID:11343241 NCBI chr 4:31,534,225...31,569,152
Ensembl chr 4:31,534,225...31,569,151
JBrowse link
G Cp ceruloplasmin increases expression EXP Sirolimus results in increased expression of CP mRNA CTD PMID:21865292 NCBI chr 2:104,744,249...104,803,034
Ensembl chr 2:104,744,461...104,799,853
JBrowse link
G Cpt1b carnitine palmitoyltransferase 1B multiple interactions EXP Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of CPT1B mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of CPT1B mRNA]] CTD PMID:25045214 NCBI chr 7:130,395,211...130,404,731
Ensembl chr 7:130,395,194...130,405,347
JBrowse link
G Cpt2 carnitine palmitoyltransferase 2 multiple interactions EXP Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of CPT2 mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of CPT2 mRNA]] CTD PMID:25045214 NCBI chr 5:127,505,646...127,523,016
Ensembl chr 5:127,505,614...127,523,089
JBrowse link
G Creb1 cAMP responsive element binding protein 1 multiple interactions ISO [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of CREB1 protein]] CTD PMID:22363816 NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
JBrowse link
G Crebrf CREB3 regulatory factor multiple interactions ISO [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of CREBRF mRNA CTD PMID:25307878 NCBI chr10:16,693,846...16,753,162
Ensembl chr10:16,694,792...16,752,205
JBrowse link
G Crtc2 CREB regulated transcription coactivator 2 decreases activity ISO Sirolimus results in decreased activity of CRTC2 protein CTD PMID:23440206 NCBI chr 2:189,615,928...189,625,646
Ensembl chr 2:189,615,948...189,626,051
JBrowse link
G Cse1l chromosome segregation 1 like decreases expression ISO Sirolimus results in decreased expression of CSE1L mRNA CTD PMID:11355896 NCBI chr 3:163,664,074...163,702,074
Ensembl chr 3:163,664,136...163,702,060
JBrowse link
G Csf1 colony stimulating factor 1 multiple interactions ISO Sirolimus inhibits the reaction [CSF1 protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [CSF1 protein results in increased phosphorylation of RPS6 protein] CTD PMID:14502240 NCBI chr 2:210,522,370...210,550,546
Ensembl chr 2:210,522,375...210,550,560
JBrowse link
G Csf2 colony stimulating factor 2 multiple interactions ISO Sirolimus inhibits the reaction [Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of CSF2 protein]] CTD PMID:1376361 NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions EXP Sirolimus promotes the reaction [Dibutyl Phthalate results in increased expression of CTNNB1 mRNA] CTD PMID:30053495 NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
JBrowse link
G Ctsk cathepsin K multiple interactions
decreases expression
ISO PDCD4 mutant form inhibits the reaction [Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased expression of CTSK mRNA]]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased activity of CTSK protein]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased expression of CTSK mRNA]
Sirolimus results in decreased expression of CTSK mRNA
CTD PMID:26369790 NCBI chr 2:196,655,469...196,666,447
Ensembl chr 2:196,655,469...196,666,446
JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 decreases expression EXP Sirolimus results in decreased expression of CXCL10 mRNA CTD PMID:21865292 NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
JBrowse link
G Cxcl13 C-X-C motif chemokine ligand 13 decreases expression EXP Sirolimus results in decreased expression of CXCL13 mRNA CTD PMID:21865292 NCBI chr14:15,253,146...15,258,221
Ensembl chr14:15,253,125...15,258,207
JBrowse link
G Cyba cytochrome b-245 alpha chain multiple interactions EXP Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of CYBA protein] CTD PMID:21195169 NCBI chr19:55,249,634...55,257,824
Ensembl chr19:55,249,616...55,257,876
JBrowse link
G Cybb cytochrome b-245 beta chain multiple interactions EXP Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of CYBB protein] CTD PMID:21195169 NCBI chr  X:14,578,330...14,610,049
Ensembl chr  X:14,578,264...14,612,547
JBrowse link
G Cyp27a1 cytochrome P450, family 27, subfamily a, polypeptide 1 multiple interactions
decreases activity
ISO [Cyclosporine co-treated with Sirolimus] results in decreased activity of CYP27A1 protein
Sirolimus results in decreased activity of CYP27A1 protein
CTD PMID:17516993 NCBI chr 9:81,968,285...81,998,213
Ensembl chr 9:81,968,332...81,998,169
JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 increases expression ISO Sirolimus results in increased expression of CYP2B6 mRNA CTD PMID:25929522 NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO
EXP
Sirolimus inhibits the reaction [arsenite results in increased expression of DDIT3 protein]; Sirolimus inhibits the reaction [Hydrogen Peroxide results in increased expression of DDIT3 protein]
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of DDIT3 mRNA; [Sirolimus results in decreased activity of MTOR protein] which results in decreased expression of DDIT3 protein; Sirolimus inhibits the reaction [arsenite results in increased expression of DDIT3 mRNA]; Sirolimus inhibits the reaction [arsenite results in increased expression of DDIT3 protein]
Sirolimus inhibits the reaction [cadmium acetate results in increased expression of DDIT3 protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased expression of DDIT3 protein]
CTD PMID:11145585, PMID:19420259, PMID:21321189, PMID:22215663, PMID:25307878, PMID:29870746 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G Ddit4l DNA-damage-inducible transcript 4-like increases expression
decreases expression
EXP Sirolimus results in increased expression of DDIT4L mRNA
Sirolimus results in decreased expression of DDIT4L mRNA
CTD PMID:21865292 NCBI chr 2:242,882,219...242,885,088
Ensembl chr 2:242,882,306...242,885,131
JBrowse link
G Deptor DEP domain containing MTOR-interacting protein multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of DEPTOR mRNA] CTD PMID:21245298 NCBI chr 7:94,795,161...95,000,750
Ensembl chr 7:94,795,214...94,995,809
JBrowse link
G Diablo diablo, IAP-binding mitochondrial protein multiple interactions ISO [7-hydroxystaurosporine co-treated with Sirolimus] affects the localization of DIABLO protein; Boc-D-FMK inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] affects the localization of DIABLO protein] CTD PMID:15767555 NCBI chr12:38,490,230...38,503,344
Ensembl chr12:38,490,230...38,503,330
JBrowse link
G Dnajc6 DnaJ heat shock protein family (Hsp40) member C6 decreases expression EXP Sirolimus results in decreased expression of DNAJC6 mRNA CTD PMID:21865292 NCBI chr 5:120,330,372...120,492,515
Ensembl chr 5:120,340,646...120,492,487
JBrowse link
G Dnmt1 DNA methyltransferase 1 multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of DNMT1 mRNA CTD PMID:19016759 NCBI chr 8:21,922,515...21,968,495
Ensembl chr 8:21,922,515...21,968,495
JBrowse link
G Dpyd dihydropyrimidine dehydrogenase decreases expression ISO Sirolimus results in decreased expression of DPYD mRNA CTD PMID:19764996 NCBI chr 2:221,823,692...222,694,627
Ensembl chr 2:221,823,687...222,694,627
JBrowse link
G Dusp10 dual specificity phosphatase 10 increases expression ISO Sirolimus results in increased expression of DUSP10 mRNA CTD PMID:24356939 NCBI chr13:104,284,660...104,321,455
Ensembl chr13:104,284,660...104,321,455
JBrowse link
G Dusp15 dual specificity phosphatase 15 decreases expression EXP Sirolimus results in decreased expression of DUSP15 mRNA CTD PMID:21865292 NCBI chr 3:148,417,990...148,428,494
Ensembl chr 3:148,417,993...148,428,494
JBrowse link
G E2f1 E2F transcription factor 1 multiple interactions ISO [TGFB1 protein co-treated with Sirolimus] results in decreased expression of E2F1 mRNA; [TGFB1 protein co-treated with Sirolimus] results in decreased expression of E2F1 protein CTD PMID:12417722 NCBI chr 3:150,062,895...150,073,721
Ensembl chr 3:150,047,826...150,073,721
JBrowse link
G E2f4 E2F transcription factor 4 multiple interactions ISO [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL1 protein] which binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL2 protein] which binds to CDK2 protein] CTD PMID:12417722 NCBI chr19:37,252,828...37,260,239
Ensembl chr19:37,252,843...37,260,239
JBrowse link
G Edn1 endothelin 1 multiple interactions EXP Sirolimus inhibits the reaction [EDN1 protein results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [EDN1 protein results in increased phosphorylation of EIF4EBP1 protein] CTD PMID:12411397 NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
JBrowse link
G Eef2 eukaryotic translation elongation factor 2 increases phosphorylation ISO Sirolimus results in increased phosphorylation of EEF2 protein CTD PMID:25940091 NCBI chr 7:11,401,501...11,406,771
Ensembl chr 7:11,401,501...11,406,771
JBrowse link
G Egf epidermal growth factor multiple interactions
decreases activity
ISO Sirolimus inhibits the reaction [EGF protein results in increased phosphorylation of MTOR protein]
Sirolimus analog results in decreased activity of EGF protein
CTD PMID:12406821, PMID:21187475 NCBI chr 2:68,820,616...68,895,537 JBrowse link
G Egfr epidermal growth factor receptor multiple interactions ISO [Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of MAPK1 protein; [Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of MAPK3 protein; [Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein] which results in increased phosphorylation of EGFR protein; AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of EGFR protein]; Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein CTD PMID:19151764 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha multiple interactions EXP Sirolimus inhibits the reaction [cadmium acetate results in increased phosphorylation of EIF2S1 protein] CTD PMID:29870746 NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
JBrowse link
G Eif4b eukaryotic translation initiation factor 4B multiple interactions
decreases phosphorylation
ISO
EXP
[resveratrol co-treated with Sirolimus] inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of EIF4B protein]; [Sirolimus co-treated with resveratrol] results in decreased phosphorylation of EIF4B protein; Sirolimus inhibits the reaction [sodium arsenite results in increased phosphorylation of EIF4B protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of EIF4B protein]
Sirolimus results in decreased phosphorylation of EIF4B protein
[resveratrol co-treated with Sirolimus] results in decreased phosphorylation of EIF4B protein
CTD PMID:21268130, PMID:24304514, PMID:24375594 NCBI chr 7:143,679,656...143,701,452
Ensembl chr 7:143,679,617...143,701,452
JBrowse link
G Eif4e eukaryotic translation initiation factor 4E multiple interactions
increases phosphorylation
decreases activity
ISO
EXP
EIF4E protein inhibits the reaction [Sirolimus results in decreased expression of MDM2 protein]
Sirolimus results in increased phosphorylation of EIF4E protein
Sirolimus inhibits the reaction [Phenylephrine results in increased phosphorylation of EIF4E protein]
Sirolimus results in decreased activity of EIF4E protein
CTD PMID:15757502, PMID:19560264, PMID:26282490 NCBI chr 2:243,819,616...243,853,987
Ensembl chr 2:243,820,661...243,852,631
JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions
affects phosphorylation
decreases phosphorylation
ISO
EXP
[Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of EIF4EBP1 protein; [Sirolimus co-treated with Cisplatin] results in decreased phosphorylation of EIF4EBP1 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of EIF4EBP1 protein; KIT protein mutant form promotes the reaction [Sirolimus results in decreased phosphorylation of EIF4EBP1 protein]; Sirolimus affects the reaction [Testosterone results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus promotes the reaction [Acetaldehyde results in decreased phosphorylation of EIF4EBP1 protein]; Sirolimus promotes the reaction [Cisplatin results in decreased phosphorylation of EIF4EBP1 protein]; Sirolimus promotes the reaction [EIF4EBP1 protein binds to 7-methylguanosine triphosphate]; Sirolimus promotes the reaction [sodium arsenite results in decreased phosphorylation of EIF4EBP1 protein]; Sirolimus results in decreased phosphorylation of and results in increased expression of EIF4EBP1 protein; sodium arsenite promotes the reaction [Sirolimus results in decreased phosphorylation of EIF4EBP1 protein]
Sirolimus affects the phosphorylation of EIF4EBP1 protein
Sirolimus inhibits the reaction [Cadmium results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [EDN1 protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [MAP2K1 protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [Phenylephrine results in increased phosphorylation of EIF4EBP1 protein]
Sirolimus inhibits the reaction [AKT1 protein mutant form results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [CSF1 protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [TNFSF11 protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus results in decreased phosphorylation of and results in increased activity of EIF4EBP1 protein; Tacrolimus inhibits the reaction [Sirolimus results in decreased phosphorylation of and results in increased activity of EIF4EBP1 protein]
CTD PMID:8599949, PMID:8971030, PMID:11909977, PMID:12411397, PMID:12939469, PMID:14502240, PMID:14673156, PMID:15782132, PMID:15806154, PMID:16255777, PMID:16597595, PMID:16962100, PMID:18021293, PMID:18058806, PMID:18622747, PMID:19478560, PMID:19560264, PMID:19853261, PMID:20169165, PMID:20863555, PMID:21036700, PMID:21321189, PMID:21898527, PMID:21933187, PMID:22869613, PMID:23363784, PMID:24299490, PMID:24375594, PMID:25940091 NCBI chr16:68,954,860...68,968,248
Ensembl chr16:68,954,875...68,968,248
JBrowse link
G Eif4g1 eukaryotic translation initiation factor 4 gamma, 1 multiple interactions ISO Sirolimus inhibits the reaction [EIF4G1 protein binds to 7-methylguanosine triphosphate]; Sirolimus inhibits the reaction [EIF4G1 protein binds to PABPC1 mRNA]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPL32 mRNA]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPS20 mRNA]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPS6 mRNA] CTD PMID:25940091 NCBI chr11:83,907,659...83,927,683
Ensembl chr11:83,908,109...83,926,524
JBrowse link
G Eif4g2 eukaryotic translation initiation factor 4, gamma 2 increases expression ISO Sirolimus results in increased expression of EIF4G2 protein CTD PMID:18491231 NCBI chr 1:175,883,362...175,895,510
Ensembl chr 1:175,883,363...175,895,510
JBrowse link
G Eno2 enolase 2 multiple interactions
increases expression
EXP 3-methyladenine inhibits the reaction [Sirolimus results in increased expression of ENO2 protein]; Chloroquine inhibits the reaction [Sirolimus results in increased expression of ENO2 protein] CTD PMID:26676567 NCBI chr 4:157,285,192...157,294,090
Ensembl chr 4:157,285,179...157,294,047
JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 multiple interactions ISO [Sirolimus co-treated with HRAS protein] results in decreased expression of ERN1 protein; PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of ERN1 protein]
Sirolimus inhibits the reaction [Palmitic Acid results in increased phosphorylation of ERN1 protein]
CTD PMID:24898257, PMID:32283200 NCBI chr10:94,588,555...94,682,072
Ensembl chr10:94,588,555...94,681,914
JBrowse link
G Ero1a endoplasmic reticulum oxidoreductase 1 alpha multiple interactions EXP Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased expression of ERO1A mRNA] CTD PMID:19420259 NCBI chr15:19,619,947...19,655,381
Ensembl chr15:19,619,973...19,655,381
JBrowse link
G Espl1 extra spindle pole bodies like 1, separase multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of ESPL1 mRNA CTD PMID:19016759 NCBI chr 7:143,896,890...143,923,868
Ensembl chr 7:143,897,014...143,923,868
JBrowse link
G Esr1 estrogen receptor 1 increases expression
increases phosphorylation
ISO Sirolimus results in increased expression of ESR1 protein
Sirolimus results in increased phosphorylation of ESR1 protein
CTD PMID:19016759 NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
JBrowse link
G Evi2a ecotropic viral integration site 2A increases expression ISO Sirolimus results in increased expression of EVI2A mRNA CTD PMID:24356939 NCBI chr10:66,870,048...66,873,948
Ensembl chr10:66,870,067...66,873,948
JBrowse link
G Ewsr1 EWS RNA-binding protein 1 decreases expression ISO Sirolimus results in decreased expression of EWSR1 protein mutant form CTD PMID:15782132 NCBI chr14:85,322,105...85,350,826
Ensembl chr14:85,322,296...85,350,948
JBrowse link
G F2 coagulation factor II decreases expression EXP Sirolimus results in decreased expression of F2 mRNA CTD PMID:21865292 NCBI chr 3:80,529,468...80,542,993
Ensembl chr 3:80,529,428...80,543,031
JBrowse link
G F3 coagulation factor III, tissue factor multiple interactions
increases activity
ISO Sirolimus promotes the reaction [TNF protein results in increased expression of F3 protein]
Sirolimus results in increased activity of F3 protein
CTD PMID:19567381 NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
JBrowse link
G Fas Fas cell surface death receptor decreases expression ISO Sirolimus results in decreased expression of FAS mRNA CTD PMID:15358118 NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
JBrowse link
G Faslg Fas ligand decreases secretion ISO Sirolimus results in decreased secretion of FASLG protein CTD PMID:11692113 NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
JBrowse link
G Faxdc2 fatty acid hydroxylase domain containing 2 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of FAXDC2 mRNA] CTD PMID:21245298 NCBI chr10:43,500,825...43,526,376
Ensembl chr10:43,502,931...43,512,287
JBrowse link
G Fbln1 fibulin 1 increases expression EXP Sirolimus results in increased expression of FBLN1 mRNA CTD PMID:21865292 NCBI chr 7:126,096,793...126,176,468
Ensembl chr 7:126,096,793...126,176,468
JBrowse link
G Fbxo32 F-box protein 32 multiple interactions
increases expression
ISO [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of FBXO32 mRNA; Sirolimus inhibits the reaction [TP73 protein results in increased expression of FBXO32 mRNA]
Sirolimus results in increased expression of FBXO32 mRNA
CTD PMID:21245298, PMID:24356939, PMID:25307878 NCBI chr 7:98,065,664...98,098,071
Ensembl chr 7:98,063,735...98,098,268
JBrowse link
G Fbxo5 F-box protein 5 multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of FBXO5 mRNA CTD PMID:19016759 NCBI chr 1:42,461,277...42,467,646
Ensembl chr 1:42,461,291...42,467,586
JBrowse link
G Fcgr1a Fc fragment of IgG receptor Ia multiple interactions
decreases expression
ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arsenic trioxide inhibits the reaction [Sirolimus results in decreased expression of FCGR1A protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [Sirolimus results in decreased expression of FCGR1A protein]; arsenic trioxide inhibits the reaction [Sirolimus results in decreased expression of FCGR1A protein] CTD PMID:25758096 NCBI chr 2:198,430,536...198,439,453
Ensembl chr 2:198,430,530...198,458,041
JBrowse link
G Fgb fibrinogen beta chain decreases expression
increases expression
EXP Sirolimus results in decreased expression of FGB mRNA
Sirolimus results in increased expression of FGB mRNA
CTD PMID:21865292 NCBI chr 2:182,028,044...182,035,026
Ensembl chr 2:182,027,115...182,038,178
JBrowse link
G Fgf1 fibroblast growth factor 1 multiple interactions EXP [Sirolimus co-treated with Hydrogen Peroxide] results in increased expression of FGF1 mRNA; Sirolimus inhibits the reaction [FGF1 protein results in increased expression of POSTN mRNA] CTD PMID:15121739, PMID:31332898 NCBI chr18:32,273,830...32,359,831
Ensembl chr18:32,273,770...32,359,824
JBrowse link
G Fgf21 fibroblast growth factor 21 multiple interactions ISO Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in increased expression of FGF21 mRNA] CTD PMID:31499194 NCBI chr 1:101,595,579...101,596,822
Ensembl chr 1:101,595,579...101,596,822
JBrowse link
G Fgf7 fibroblast growth factor 7 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of FGF7 mRNA] CTD PMID:21245298 NCBI chr 3:118,315,859...118,368,464
Ensembl chr 3:118,317,761...118,366,872
JBrowse link
G Fkbp1a FKBP prolyl isomerase 1A affects binding
multiple interactions
ISO
EXP
Sirolimus binds to FKBP1A protein
immunomycin inhibits the reaction [Sirolimus binds to FKBP1A protein]
[Sirolimus binds to FKBP1A protein] which results in decreased expression of IL2RG mRNA; [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL2RG protein; [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL4R mRNA; [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL4R protein; [Sirolimus binds to FKBP1A protein] which results in increased expression of ACTB mRNA; immunomycin inhibits the reaction [Sirolimus binds to FKBP1A protein]
[Sirolimus binds to FKBP1A protein] which results in increased activity of TGFB1 protein; [Tacrolimus binds to FKBP1A protein] inhibits the reaction [Sirolimus binds to FKBP1A protein]
CTD PMID:7503980, PMID:7532117, PMID:10361256, PMID:12417722, PMID:12531798, PMID:17438408 NCBI chr 3:147,042,944...147,062,725
Ensembl chr 3:147,042,944...147,062,724
JBrowse link
G Flt3lg Fms related receptor tyrosine kinase 3 ligand decreases activity ISO Sirolimus results in decreased activity of FLT3LG protein CTD PMID:12531798 NCBI chr 1:101,126,006...101,131,413
Ensembl chr 1:101,124,479...101,131,413
JBrowse link
G Folr1 folate receptor alpha multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of FOLR1 mRNA] CTD PMID:21245298 NCBI chr 1:166,934,457...166,945,864
Ensembl chr 1:166,934,460...166,943,592
JBrowse link
G Foxm1 forkhead box M1 multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of FOXM1 mRNA CTD PMID:19016759 NCBI chr 4:161,685,236...161,697,633
Ensembl chr 4:161,685,258...161,696,305
JBrowse link
G Foxo1 forkhead box O1 increases phosphorylation ISO Sirolimus results in increased phosphorylation of FOXO1 protein CTD PMID:16227402 NCBI chr 2:141,451,234...141,527,016
Ensembl chr 2:141,451,234...141,527,016
JBrowse link
G Foxo3 forkhead box O3 multiple interactions
increases phosphorylation
ISO [Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of BCL2L11 protein; [Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of CDKN1B protein; Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]; Sirolimus promotes the reaction [Cisplatin results in increased expression of and results in increased localization of and results in increased activity of FOXO3 protein]; Sirolimus results in decreased degradation of and results in increased phosphorylation of FOXO3 protein CTD PMID:21092744 NCBI chr20:46,428,078...46,519,156
Ensembl chr20:46,428,124...46,519,144
JBrowse link
G Foxp1 forkhead box P1 decreases expression ISO Sirolimus results in decreased expression of FOXP1 protein CTD PMID:25663935 NCBI chr 4:131,362,178...131,963,466
Ensembl chr 4:131,366,744...131,694,755
JBrowse link
G Foxp3 forkhead box P3 multiple interactions
increases expression
ISO [TGFB1 protein modified form co-treated with Sirolimus] results in increased expression of FOXP3 mRNA; [TGFB1 protein modified form co-treated with Sirolimus] results in increased expression of FOXP3 protein
Sirolimus results in increased expression of FOXP3 mRNA
CTD PMID:20844194 NCBI chr  X:15,753,175...15,768,648
Ensembl chr  X:15,753,175...15,768,522
JBrowse link
G Frat1 FRAT regulator of WNT signaling pathway 1 increases expression ISO Sirolimus results in increased expression of FRAT1 mRNA CTD PMID:24356939 NCBI chr 1:261,071,965...261,075,244 JBrowse link
G Fshb follicle stimulating hormone subunit beta multiple interactions EXP Sirolimus inhibits the reaction [FSHB protein results in increased expression of CCND2 mRNA] CTD PMID:17510244 NCBI chr 3:98,088,321...98,092,131
Ensembl chr 3:98,088,324...98,092,131
JBrowse link
G Ftl1 ferritin light chain 1 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of FTL mRNA] CTD PMID:21245298 NCBI chr 1:101,448,190...101,450,034
Ensembl chr 1:101,448,346...101,449,829
JBrowse link
G Gabarap GABA type A receptor-associated protein increases expression ISO Sirolimus results in increased expression of GABARAP mRNA CTD PMID:21681844 NCBI chr10:56,601,288...56,604,223
Ensembl chr10:56,601,288...56,604,221
JBrowse link
G Gabarapl1 GABA type A receptor associated protein like 1 multiple interactions ISO Sirolimus affects the localization of and results in increased lipidation of GABARAPL1 protein CTD PMID:15888080 NCBI chr 4:163,293,724...163,302,866
Ensembl chr 4:163,293,724...163,302,858
JBrowse link
G Gcm2 glial cells missing transcription factor 2 multiple interactions ISO Sirolimus promotes the reaction [TP73 protein affects the activity of GCM2 protein] CTD PMID:21245298 NCBI chr17:21,490,402...21,499,516
Ensembl chr17:21,490,402...21,499,516
JBrowse link
G Gem GTP binding protein overexpressed in skeletal muscle multiple interactions ISO [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of GEM mRNA CTD PMID:25307878 NCBI chr 5:25,339,479...25,353,661
Ensembl chr 5:25,349,928...25,353,661
JBrowse link
G Ggt1 gamma-glutamyltransferase 1 multiple interactions EXP Sirolimus promotes the reaction [Cyclosporine affects the expression of GGT1 protein] CTD PMID:11589784 NCBI chr20:14,019,723...14,045,781
Ensembl chr20:14,019,723...14,025,068
JBrowse link
G Glb1 galactosidase, beta 1 multiple interactions
decreases expression
EXP Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]]; Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]]
Sirolimus results in decreased expression of GLB1 protein
CTD PMID:22561310 NCBI chr 8:122,439,328...122,511,939
Ensembl chr 8:122,439,328...122,511,939
JBrowse link
G Gper1 G protein-coupled estrogen receptor 1 multiple interactions ISO Sirolimus inhibits the reaction [puerarin results in increased expression of GPER1 protein] CTD PMID:27796870 NCBI chr12:17,309,122...17,315,267
Ensembl chr12:17,309,834...17,311,112
JBrowse link
G Gpnmb glycoprotein nmb increases expression EXP Sirolimus results in increased expression of GPNMB mRNA CTD PMID:21865292 NCBI chr 4:78,694,447...78,715,685
Ensembl chr 4:78,694,447...78,715,683
JBrowse link
G Gpr18 G protein-coupled receptor 18 increases expression ISO Sirolimus results in increased expression of GPR18 mRNA CTD PMID:24356939 NCBI chr15:108,323,157...108,326,907
Ensembl chr15:108,323,179...108,326,907
JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions EXP
ISO
Sirolimus promotes the reaction [Cyclosporine affects the expression of GPT protein]
Sirolimus inhibits the reaction [Ethylene Chlorohydrin promotes the reaction [Lipopolysaccharides results in increased activity of GPT protein]]
CTD PMID:11589784, PMID:31499194 NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions
increases activity
ISO [3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [Lithium Chloride results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [SB 216763 results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [Sirolimus results in decreased activity of MTOR protein] which results in increased phosphorylation of GSK3B protein; [Sirolimus results in increased activity of GSK3B protein] which results in increased phosphorylation of and results in increased degradation of CCND1 protein
Sirolimus inhibits the reaction [TSC1 gene mutant form results in decreased phosphorylation of GSK3B protein]
CTD PMID:15753396, PMID:17908691, PMID:18495876 NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
JBrowse link
G Gstt1 glutathione S-transferase theta 1 increases response to substance ISO GSTT1 gene mutant form results in increased susceptibility to Sirolimus CTD PMID:12916871 NCBI chr20:13,799,102...13,816,527
Ensembl chr20:13,799,102...13,816,526
JBrowse link
G Gtpbp4 GTP binding protein 4 decreases expression EXP Sirolimus results in decreased expression of GTPBP4 mRNA CTD PMID:21865292 NCBI chr17:63,111,086...63,145,618
Ensembl chr17:63,110,254...63,145,577
JBrowse link
G Guca2a guanylate cyclase activator 2A increases expression EXP Sirolimus results in increased expression of GUCA2A mRNA CTD PMID:21865292 NCBI chr 5:138,685,634...138,687,476
Ensembl chr 5:138,685,624...138,687,816
JBrowse link
G Gzmb granzyme B decreases expression ISO Sirolimus results in decreased expression of GZMB protein CTD PMID:16477233 NCBI chr15:35,413,862...35,417,293
Ensembl chr15:35,413,793...35,417,316
JBrowse link
G H2ax H2A.X variant histone decreases expression ISO Sirolimus results in decreased expression of H2AX protein CTD PMID:23363784 NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 increases expression EXP Sirolimus results in increased expression of HAVCR1 mRNA CTD PMID:21865292 NCBI chr10:31,813,819...31,860,934
Ensembl chr10:31,813,814...31,848,379
JBrowse link
G Hbp1 HMG-box transcription factor 1 multiple interactions ISO [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of HBP1 mRNA; Sirolimus inhibits the reaction [PIK3CA protein modified form results in decreased expression of HBP1 mRNA] CTD PMID:25307878, PMID:27542212 NCBI chr 6:51,231,479...51,257,699
Ensembl chr 6:51,231,480...51,257,625
JBrowse link
G Hes1 hes family bHLH transcription factor 1 decreases expression ISO Sirolimus results in decreased expression of HES1 protein
Sirolimus results in decreased expression of HES1 mRNA; Sirolimus results in decreased expression of HES1 protein
CTD PMID:20038814 NCBI chr11:74,312,837...74,315,249
Ensembl chr11:74,312,806...74,315,248
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions
decreases expression
ISO
EXP
[Curcumin analog co-treated with Sirolimus] inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [4-hydroxyestradiol results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A mRNA]; Sirolimus inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [sulprostone results in increased expression of HIF1A protein]
Sirolimus results in decreased expression of HIF1A mRNA
Sirolimus results in decreased expression of HIF1A protein
CTD PMID:15050414, PMID:15297429, PMID:15634505, PMID:16682453, PMID:17968710, PMID:19335982, PMID:19640849, PMID:20335389, PMID:20554536, PMID:21984483, PMID:28574600 NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase increases expression ISO Sirolimus results in increased expression of HMGCR mRNA CTD PMID:17516993 NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
JBrowse link
G Hmox1 heme oxygenase 1 increases expression
multiple interactions
ISO
EXP
Sirolimus results in increased expression of HMOX1
Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased expression of HMOX1 protein]
CTD PMID:17003813, PMID:19420259 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Hnrnpd heterogeneous nuclear ribonucleoprotein D decreases expression
increases expression
ISO
EXP
Sirolimus results in decreased expression of HNRNPD protein
Sirolimus results in increased expression of HNRNPD protein
CTD PMID:17603996 NCBI chr14:11,256,163...11,274,684
Ensembl chr14:11,256,268...11,274,578
JBrowse link
G Hoxa9 homeobox A9 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein affects the activity of HOXA9 protein] CTD PMID:21245298
G Hras HRas proto-oncogene, GTPase multiple interactions ISO [Sirolimus co-treated with HRAS protein] results in decreased expression of ERN1 protein; [Sirolimus co-treated with HRAS protein] results in decreased expression of HSPA5 protein; PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of ERN1 protein]; PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of HSPA5 protein]
Sirolimus inhibits the reaction [HRAS protein mutant form results in increased expression of MIR146A mRNA]; Sirolimus inhibits the reaction [HRAS protein mutant form results in increased expression of MIR193A-1 mRNA]; Sirolimus inhibits the reaction [HRAS protein mutant form results in increased expression of MIR21-1 mRNA]; Sirolimus inhibits the reaction [HRAS protein mutant form results in increased expression of MIR21-2 mRNA]; Sirolimus inhibits the reaction [HRAS protein mutant form results in increased phosphorylation of RPS6 protein]
CTD PMID:24898257, PMID:30619488 NCBI chr 1:214,178,404...214,181,841
Ensembl chr 1:214,178,407...214,181,686
JBrowse link
G Hspa1b heat shock protein family A (Hsp70) member 1B decreases expression ISO Sirolimus results in decreased expression of HSPA1B mRNA CTD PMID:24356939 NCBI chr20:4,877,638...4,880,112
Ensembl chr20:2,699,712...2,701,815
JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 decreases expression
multiple interactions
ISO
EXP
Sirolimus results in decreased expression of HSPA5 mRNA
Sirolimus inhibits the reaction [cadmium acetate results in increased expression of HSPA5 protein]
[Sirolimus co-treated with HRAS protein] results in decreased expression of HSPA5 protein; PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of HSPA5 protein]
CTD PMID:24356939, PMID:24898257, PMID:29870746 NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
JBrowse link
G Hspb8 heat shock protein family B (small) member 8 decreases expression ISO Sirolimus results in decreased expression of HSPB8 protein CTD PMID:21233418 NCBI chr12:45,905,371...45,920,014
Ensembl chr12:45,905,371...45,920,013
JBrowse link
G Ibsp integrin-binding sialoprotein multiple interactions ISO Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased expression of IBSP protein] CTD PMID:31051157 NCBI chr14:6,801,200...6,813,987
Ensembl chr14:6,801,204...6,813,945
JBrowse link
G Icam1 intercellular adhesion molecule 1 decreases expression ISO Sirolimus results in decreased expression of ICAM1 protein CTD PMID:12531798 NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
JBrowse link
G Id1 inhibitor of DNA binding 1, HLH protein increases expression ISO Sirolimus results in increased expression of ID1 mRNA CTD PMID:23824090, PMID:24356939 NCBI chr 3:148,214,623...148,216,715
Ensembl chr 3:148,215,540...148,216,718
JBrowse link
G Ifng interferon gamma multiple interactions
decreases secretion
ISO Sirolimus inhibits the reaction [IFNG protein results in decreased phosphorylation of STAT3 protein]
Sirolimus inhibits the reaction [Lipopolysaccharides results in increased secretion of IFNG protein]
Sirolimus results in decreased secretion of IFNG protein
CTD PMID:11692113, PMID:16427044, PMID:21600178 NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
JBrowse link
G Igf1 insulin-like growth factor 1 multiple interactions
increases response to substance
ISO
EXP
[Dexamethasone co-treated with Sirolimus] inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6KB1 protein]; [Dexamethasone co-treated with Sirolimus] results in decreased activity of IGF1 protein; [Sirolimus co-treated with IGF1 protein] results in increased expression of ACTA2 protein; [Sirolimus co-treated with IGF1 protein] results in increased expression of CALD1 protein; [Sirolimus co-treated with IGF1 protein] results in increased expression of MYH11 protein; Sirolimus inhibits the reaction [IGF1 protein results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased secretion of IGFBP3 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased secretion of VEGFA protein]
Sirolimus inhibits the reaction [[IGF1 protein co-treated with U 0126] promotes the reaction [Isoflurane results in decreased phosphorylation of MAPK1 protein]]; Sirolimus inhibits the reaction [IGF1 protein affects the localization of CDKN1A protein]; Sirolimus inhibits the reaction [IGF1 protein affects the localization of CDKN1B protein]; Sirolimus inhibits the reaction [IGF1 protein inhibits the reaction [Isoflurane results in decreased phosphorylation of AKT1 protein]]; Sirolimus inhibits the reaction [IGF1 protein results in increased expression of CCND1 protein]
Sirolimus results in increased susceptibility to IGF1 protein
Sirolimus inhibits the reaction [IL2 protein results in increased expression of IGF1 mRNA]
CTD PMID:11355896, PMID:15070696, PMID:15297429, PMID:16227402, PMID:16682453, PMID:17908691, PMID:19105244, PMID:25597859 NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
JBrowse link
G Igf1r insulin-like growth factor 1 receptor affects activity
multiple interactions
ISO Sirolimus affects the activity of IGF1R protein
Sirolimus promotes the reaction [IGF1R protein binds to and results in increased phosphorylation of IRS1 protein]
CTD PMID:16227402 NCBI chr 1:128,924,921...129,213,816
Ensembl chr 1:128,924,966...129,206,516
JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 increases expression EXP Sirolimus results in increased expression of IGFBP1 mRNA CTD PMID:21865292 NCBI chr14:87,448,716...87,453,783
Ensembl chr14:87,448,692...87,453,785
JBrowse link
G Igfbp3 insulin-like growth factor binding protein 3 multiple interactions ISO Sirolimus inhibits the reaction [IGF1 protein results in increased secretion of IGFBP3 protein] CTD PMID:16682453 NCBI chr14:87,457,647...87,465,374
Ensembl chr14:87,457,647...87,465,374
JBrowse link
G Igfbp5 insulin-like growth factor binding protein 5 decreases expression EXP Sirolimus results in decreased expression of IGFBP5 mRNA CTD PMID:21865292 NCBI chr 9:80,154,230...80,166,813
Ensembl chr 9:80,150,211...80,167,033
JBrowse link
G Il10 interleukin 10 multiple interactions
decreases expression
ISO Sirolimus inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 protein]; Sirolimus inhibits the reaction [lipoteichoic acid results in increased expression of IL10 protein]; Sirolimus inhibits the reaction [Peptidoglycan results in increased expression of IL10 protein]
Sirolimus results in decreased expression of IL10 mRNA
Sirolimus results in decreased expression of IL10 protein
[Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL10 protein; Sirolimus inhibits the reaction [Ethylene Chlorohydrin promotes the reaction [Lipopolysaccharides results in increased expression of IL10 mRNA]]
CTD PMID:11169223, PMID:15588918, PMID:31499194 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
JBrowse link
G Il12a interleukin 12A multiple interactions ISO Sirolimus inhibits the reaction [IL4 protein results in increased expression of [IL12A protein binds to IL12B protein]] CTD PMID:12531798 NCBI chr 2:165,076,945...165,083,996
Ensembl chr 2:165,076,607...165,084,318
JBrowse link
G Il12b interleukin 12B multiple interactions ISO Sirolimus inhibits the reaction [IL4 protein results in increased expression of [IL12A protein binds to IL12B protein]] CTD PMID:12531798 NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
JBrowse link
G Il17rb interleukin 17 receptor B multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of IL17RB mRNA CTD PMID:19016759 NCBI chr16:6,064,287...6,077,978
Ensembl chr16:6,064,288...6,077,978
JBrowse link
G Il18 interleukin 18 multiple interactions ISO Sirolimus inhibits the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased expression of IL18 protein] CTD PMID:30205151 NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases expression
affects expression
ISO
EXP
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; Sirolimus inhibits the reaction [Ethylene Chlorohydrin promotes the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]
Sirolimus inhibits the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased expression of IL1B protein]
Sirolimus results in increased expression of IL1B mRNA
Sirolimus inhibits the reaction [[Zearalenone co-treated with Lipopolysaccharides] results in increased expression of IL1B protein modified form]; Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL1B mRNA]; Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL1B protein]; Sirolimus inhibits the reaction [Pilocarpine results in increased expression of IL1B mRNA]; Sirolimus inhibits the reaction [Pilocarpine results in increased expression of IL1B protein]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL1B mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL1B protein]]
Sirolimus results in increased expression of IL1B protein
Sirolimus affects the expression of IL1B mRNA
CTD PMID:22363816, PMID:23211629, PMID:24971338, PMID:25045214, PMID:29594315, PMID:30205151, PMID:31499194, PMID:31586597 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il2 interleukin 2 multiple interactions
affects expression
decreases response to substance
ISO
EXP
[Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased expression of CCND2 protein]; [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased expression of CCND3 protein]; [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased phosphorylation of RB1 protein]; [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; Sirolimus inhibits the reaction [IL2 protein results in increased expression of CCND2 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of CCND3 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RB1 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RBL2 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]
Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL2 mRNA]; Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL2 protein]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL2 mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL2 protein]]
Sirolimus affects the expression of IL2 protein
[Sirolimus co-treated with IL2 protein] results in decreased expression of BCL2A1A mRNA; [Sirolimus co-treated with IL2 protein] results in increased expression of BCL2 mRNA; [Sirolimus co-treated with IL2 protein] results in increased expression of BCL2L1 mRNA; [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 protein; Sirolimus inhibits the reaction [IL2 protein results in decreased expression of CCNI mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of ASNS mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of BAD mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of BNIP3 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of BTK mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of CDK1 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of IGF1 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of MCM2 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of MCM7 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of PCNA mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]; Tacrolimus inhibits the reaction [Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]]
Sirolimus results in decreased susceptibility to IL2 protein
CTD PMID:1614535, PMID:10373522, PMID:11355896, PMID:15588918, PMID:15778701, PMID:24971338, PMID:25045214, PMID:29594315 NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
JBrowse link
G Il2ra interleukin 2 receptor subunit alpha multiple interactions ISO Sirolimus inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2RA protein]; Sirolimus inhibits the reaction [Ionomycin results in increased secretion of IL2RA protein]; Sirolimus inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of IL2RA protein] CTD PMID:8586487 NCBI chr17:70,500,672...70,547,929
Ensembl chr17:70,499,083...70,548,071
JBrowse link
G Il2rg interleukin 2 receptor subunit gamma multiple interactions ISO [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL2RG mRNA; [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL2RG protein CTD PMID:12531798 NCBI chr  X:71,165,378...71,169,078
Ensembl chr  X:71,162,585...71,169,865
JBrowse link
G Il3 interleukin 3 multiple interactions ISO Sirolimus inhibits the reaction [Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL3 protein]] CTD PMID:1376361 NCBI chr10:39,620,535...39,622,973
Ensembl chr10:39,620,563...39,622,973
JBrowse link
G Il4 interleukin 4 multiple interactions
decreases expression
ISO [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL4 protein; Sirolimus inhibits the reaction [IL4 protein results in increased expression of [IL12A protein binds to IL12B protein]]
Sirolimus analog results in decreased expression of IL4 protein; Sirolimus results in decreased expression of IL4 protein
CTD PMID:12406821, PMID:12531798, PMID:15588918 NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
JBrowse link
G Il4r interleukin 4 receptor multiple interactions ISO [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL4R mRNA; [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL4R protein CTD PMID:12531798 NCBI chr 1:196,942,343...196,967,221
Ensembl chr 1:196,942,364...196,967,220
JBrowse link
G Il5 interleukin 5 decreases expression ISO Sirolimus analog results in decreased expression of IL5 protein CTD PMID:12406821 NCBI chr10:39,066,716...39,069,587
Ensembl chr10:39,066,716...39,069,587
JBrowse link
G Il6 interleukin 6 multiple interactions
increases expression
decreases expression
ISO [Dexamethasone co-treated with Sirolimus] inhibits the reaction [IL6 protein results in increased phosphorylation of RPS6KB1 protein]; [Dexamethasone co-treated with Sirolimus] results in decreased activity of IL6 protein; [TGFB1 protein modified form co-treated with Sirolimus] results in decreased expression of IL6 mRNA; [TGFB1 protein modified form co-treated with Sirolimus] results in decreased expression of IL6 protein
Sirolimus results in increased expression of IL6
Sirolimus results in decreased expression of IL6 mRNA
CTD PMID:15070696, PMID:16314788, PMID:20844194 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Ing4 inhibitor of growth family, member 4 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of ING4 mRNA] CTD PMID:21245298 NCBI chr 4:157,554,729...157,563,353
Ensembl chr 4:157,554,794...157,563,352
JBrowse link
G Ins2 insulin 2 multiple interactions ISO Sirolimus inhibits the reaction [cyanoginosin LR promotes the reaction [INS protein results in increased expression of RPS6KB1 protein modified form]]; Sirolimus inhibits the reaction [cyanoginosin LR promotes the reaction [INS protein results in increased phosphorylation of IRS1 protein]]; Sirolimus inhibits the reaction [INS protein promotes the reaction [cyanoginosin LR results in increased expression of RPS6KB1 protein modified form]]; Sirolimus inhibits the reaction [INS protein promotes the reaction [cyanoginosin LR results in increased phosphorylation of IRS1 protein]]; Sirolimus inhibits the reaction [INS protein results in increased expression of IRS1 protein modified form]; Sirolimus inhibits the reaction [INS protein results in increased expression of MAPK1 protein modified form]; Sirolimus inhibits the reaction [INS protein results in increased expression of MAPK3 protein modified form]; Sirolimus inhibits the reaction [INS protein results in increased expression of RPS6KB1 protein modified form]; Sirolimus inhibits the reaction [INS protein results in increased phosphorylation of IRS1 protein]; Sirolimus inhibits the reaction [INS protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [Palmitic Acid inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]] CTD PMID:20936651, PMID:28790194, PMID:28984034, PMID:32283200 NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
JBrowse link
G Insig1 insulin induced gene 1 multiple interactions ISO [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of INSIG1 mRNA CTD PMID:25307878 NCBI chr 4:342,302...350,515
Ensembl chr 4:342,302...350,515
JBrowse link
G Irs1 insulin receptor substrate 1 affects phosphorylation
decreases phosphorylation
decreases degradation
multiple interactions
ISO Sirolimus affects the phosphorylation of IRS1 protein
Sirolimus results in decreased phosphorylation of IRS1 protein
Sirolimus results in decreased degradation of IRS1 protein
[Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased activity of IRS1 protein; Sirolimus inhibits the reaction [cyanoginosin LR promotes the reaction [INS protein results in increased phosphorylation of IRS1 protein]]; Sirolimus inhibits the reaction [cyanoginosin LR results in increased phosphorylation of IRS1 protein]; Sirolimus inhibits the reaction [INS protein promotes the reaction [cyanoginosin LR results in increased phosphorylation of IRS1 protein]]; Sirolimus inhibits the reaction [INS protein results in increased expression of IRS1 protein modified form]; Sirolimus inhibits the reaction [INS protein results in increased phosphorylation of IRS1 protein]; Sirolimus promotes the reaction [IGF1R protein binds to and results in increased phosphorylation of IRS1 protein]; Sirolimus promotes the reaction [IRS1 protein binds to PIK3R1 protein]
CTD PMID:16227402, PMID:17908691, PMID:20936651, PMID:28984034 NCBI chr 9:88,033,668...88,086,488
Ensembl chr 9:88,033,668...88,086,488
JBrowse link
G Itgam integrin subunit alpha M multiple interactions
increases expression
ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Sirolimus co-treated with arsenic trioxide] results in increased expression of ITGAM protein]; [Sirolimus co-treated with arsenic trioxide] results in increased expression of ITGAM protein; Sirolimus promotes the reaction [Tretinoin results in increased localization of and results in increased expression of ITGAM protein]
Sirolimus results in increased expression of ITGAM protein
CTD PMID:20574048, PMID:25758096 NCBI chr 1:199,495,312...199,545,738
Ensembl chr 1:199,495,298...199,623,960
JBrowse link
G Itgav integrin subunit alpha V decreases expression ISO Sirolimus results in decreased expression of ITGAV mRNA; Sirolimus results in decreased expression of ITGAV protein CTD PMID:19922502 NCBI chr 3:71,113,269...71,205,958
Ensembl chr 3:71,114,100...71,202,411
JBrowse link
G Jag1 jagged canonical Notch ligand 1 decreases expression ISO Sirolimus results in decreased expression of JAG1 protein CTD PMID:20038814 NCBI chr 3:130,079,361...130,114,781
Ensembl chr 3:130,079,361...130,114,770
JBrowse link
G Jmy junction mediating and regulatory protein, p53 cofactor multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in decreased expression of JMY mRNA] CTD PMID:21245298 NCBI chr 2:23,026,506...23,097,702
Ensembl chr 2:23,042,189...23,097,610
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased phosphorylation of JUN protein] CTD PMID:26369790 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Kifap3 kinesin-associated protein 3 increases expression EXP Sirolimus results in increased expression of KIFAP3 mRNA CTD PMID:21865292 NCBI chr13:82,072,497...82,217,256
Ensembl chr13:82,072,497...82,217,252
JBrowse link
G Kifc1 kinesin family member C1 decreases expression EXP Sirolimus results in decreased expression of KIFC1 mRNA CTD PMID:21865292 NCBI chr20:5,509,059...5,526,175
Ensembl chr20:5,509,059...5,526,175
JBrowse link
G Kit KIT proto-oncogene receptor tyrosine kinase multiple interactions ISO KIT protein mutant form promotes the reaction [Sirolimus results in decreased phosphorylation of EIF4EBP1 protein] CTD PMID:16597595 NCBI chr14:35,072,131...35,149,638
Ensembl chr14:35,072,108...35,149,610
JBrowse link
G Kitlg KIT ligand multiple interactions ISO Sirolimus inhibits the reaction [KITL protein results in increased expression of CCND3 protein]; Sirolimus inhibits the reaction [KITL protein results in increased phosphorylation of RB1 protein] CTD PMID:10849422 NCBI chr 7:42,269,784...42,351,054
Ensembl chr 7:42,269,784...42,351,054
JBrowse link
G Klf2 Kruppel-like factor 2 increases expression ISO Sirolimus results in increased expression of KLF2 mRNA CTD PMID:24356939 NCBI chr16:19,223,087...19,225,037
Ensembl chr16:19,223,087...19,225,037
JBrowse link
G Klf5 Kruppel-like factor 5 increases expression EXP Sirolimus results in increased expression of KLF5 mRNA CTD PMID:21865292 NCBI chr15:83,703,796...83,722,921
Ensembl chr15:83,703,791...83,722,921
JBrowse link
G Klf6 Kruppel-like factor 6 decreases phosphorylation ISO Sirolimus results in decreased phosphorylation of KLF6 protein CTD PMID:16611854 NCBI chr17:67,887,939...67,945,052
Ensembl chr17:67,887,939...67,945,037
JBrowse link
G Klhl24 kelch-like family member 24 increases expression
multiple interactions
ISO Sirolimus results in increased expression of KLHL24 mRNA
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of KLHL24 mRNA
CTD PMID:24356939, PMID:25307878 NCBI chr11:84,613,101...84,643,674
Ensembl chr11:84,615,760...84,633,504
JBrowse link
G Klk1c10 kallikrein 1-related peptidase C10 decreases expression EXP Sirolimus results in decreased expression of KLK1C10 mRNA CTD PMID:21865292 NCBI chr 1:99,890,294...99,894,353
Ensembl chr 1:99,890,294...99,894,353
JBrowse link
G Klk1c9 kallikrein 1-related peptidase C9 decreases expression EXP Sirolimus results in decreased expression of KLK1C9 mRNA CTD PMID:21865292 NCBI chr 1:100,086,520...100,090,406
Ensembl chr 1:100,059,967...100,203,329
JBrowse link
G L1cam L1 cell adhesion molecule affects response to substance ISO L1CAM affects the susceptibility to Sirolimus CTD PMID:21097529 NCBI chr  X:156,901,244...156,928,064
Ensembl chr  X:156,909,913...156,928,057
JBrowse link
G Lamc2 laminin subunit gamma 2 increases expression EXP Sirolimus results in increased expression of LAMC2 mRNA CTD PMID:21865292 NCBI chr13:70,566,643...70,632,126
Ensembl chr13:70,566,643...70,626,252
JBrowse link
G Larp1 La ribonucleoprotein 1, translational regulator multiple interactions
increases response to substance
ISO LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPL32 protein]; LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPS20 protein]; LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPS6 protein]; Sirolimus inhibits the reaction [[MTOR protein binds to RAPTOR protein] which binds to LARP1 protein]; Sirolimus promotes the reaction [LARP1 protein binds to PABPC1 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to RPL32 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to RPS20 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to RPS6 mRNA]
LARP1 protein results in increased susceptibility to Sirolimus
CTD PMID:25940091 NCBI chr10:43,435,738...43,501,186
Ensembl chr10:43,446,526...43,498,066
JBrowse link
G Lcn2 lipocalin 2 increases expression EXP Sirolimus results in increased expression of LCN2 mRNA CTD PMID:21865292 NCBI chr 3:11,414,189...11,417,534
Ensembl chr 3:11,414,186...11,417,546
JBrowse link
G Lipe lipase E, hormone sensitive type multiple interactions ISO Sirolimus promotes the reaction [Isoproterenol results in increased phosphorylation of LIPE protein] CTD PMID:21042876 NCBI chr 1:82,248,031...82,266,727
Ensembl chr 1:82,248,046...82,266,727
JBrowse link
G Mad2l1 mitotic arrest deficient 2 like 1 multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of MAD2L1 mRNA CTD PMID:19016759 NCBI chr 4:97,530,993...97,543,179
Ensembl chr 4:97,531,083...97,537,086
JBrowse link
G Maf1 MAF1 homolog, negative regulator of RNA polymerase III multiple interactions ISO [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Sirolimus] results in decreased degradation of MAF1 protein; Cycloheximide inhibits the reaction [Sirolimus results in increased expression of MAF1 protein]; Sirolimus results in increased expression of and results in decreased phosphorylation of MAF1 protein CTD PMID:31645432 NCBI chr 7:117,417,643...117,420,722
Ensembl chr 7:117,417,687...117,420,719
JBrowse link
G Map1lc3a microtubule-associated protein 1 light chain 3 alpha multiple interactions ISO [Sirolimus inhibits the reaction [MTOR protein binds to RPTOR protein]] which results in increased expression of MAP1LC3A protein alternative form CTD PMID:21742779 NCBI chr 3:150,801,289...150,802,935
Ensembl chr 3:150,801,289...150,802,935
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta increases expression
increases lipidation
multiple interactions
affects metabolic processing
affects localization
ISO
EXP
Sirolimus results in increased expression of MAP1LC3B mRNA; Sirolimus results in increased expression of MAP1LC3B protein; Sirolimus results in increased expression of MAP1LC3B protein modified form
Sirolimus results in increased lipidation of MAP1LC3B protein
Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased cleavage of MAP1LC3B protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased cleavage of MAP1LC3B protein]; Sirolimus promotes the reaction [Caffeine results in increased cleavage of MAP1LC3B protein]; Sirolimus promotes the reaction [TNF protein results in increased expression of and results in increased lipidation of MAP1LC3B protein]
CD38 gene mutant form promotes the reaction [Sirolimus results in increased expression of MAP1LC3B protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in decreased expression of MAP1LC3B protein]; Sirolimus promotes the reaction [Tunicamycin results in increased lipidation of MAP1LC3B protein]
Sirolimus affects the metabolism of MAP1LC3B protein
Sirolimus results in increased expression of MAP1LC3B mRNA; Sirolimus results in increased expression of MAP1LC3B protein modified form
3-methyladenine inhibits the reaction [Sirolimus results in increased expression of MAP1LC3B protein modified form]; saikosaponin inhibits the reaction [Sirolimus results in increased cleavage of MAP1LC3B protein]; Sirolimus inhibits the reaction [saikosaponin results in decreased cleavage of MAP1LC3B protein]; Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased cleavage of MAP1LC3B protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased cleavage of MAP1LC3B protein]; Sirolimus promotes the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in decreased expression of MAP1LC3B protein]]; Sirolimus results in increased expression of and results in increased cleavage of MAP1LC3B protein
Sirolimus affects the localization of MAP1LC3B protein
CTD PMID:18640276, PMID:19815708, PMID:21212465, PMID:21681844, PMID:23680031, PMID:24445604, PMID:25884947, PMID:27107786, PMID:29128638, PMID:29518472, PMID:29793971, PMID:30338810, PMID:30555576, PMID:30611790, PMID:31676321 NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
JBrowse link
G Map2 microtubule-associated protein 2 multiple interactions
increases expression
EXP 3-methyladenine inhibits the reaction [Sirolimus results in increased expression of MAP2 protein]; Chloroquine inhibits the reaction [Sirolimus results in increased expression of MAP2 protein] CTD PMID:26676567 NCBI chr 9:73,204,753...73,462,965
Ensembl chr 9:73,319,710...73,462,972
JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions ISO
EXP
[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of MAP2K1 protein; [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of MAP2K1 protein
Sirolimus inhibits the reaction [MAP2K1 protein results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [MAP2K1 protein results in increased phosphorylation of EIF4EBP1 protein]
CTD PMID:12411397, PMID:15767555 NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
JBrowse link
G Map2k2 mitogen activated protein kinase kinase 2 multiple interactions ISO [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of MAP2K2 protein CTD PMID:15767555 NCBI chr 7:11,458,971...11,478,520
Ensembl chr 7:11,458,967...11,478,489
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
affects phosphorylation
increases phosphorylation
decreases phosphorylation
ISO
EXP
[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of MAPK1 protein; AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK1 protein]; Arsenic Trioxide inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Sirolimus inhibits the reaction [INS protein results in increased expression of MAPK1 protein modified form]
Sirolimus affects the phosphorylation of MAPK1 protein
Sirolimus inhibits the reaction [[IGF1 protein co-treated with U 0126] promotes the reaction [Isoflurane results in decreased phosphorylation of MAPK1 protein]]
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]]; [Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of MAPK1 protein; [Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein] which results in increased phosphorylation of MAPK1 protein; AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK1 protein]
Sirolimus results in decreased phosphorylation of MAPK1 protein
CTD PMID:15767555, PMID:16255777, PMID:18374093, PMID:19151764, PMID:20936651, PMID:21984483, PMID:22363816, PMID:24392034, PMID:25597859, PMID:25758096, PMID:30905858 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
affects phosphorylation
increases phosphorylation
decreases phosphorylation
ISO
EXP
[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of MAPK3 protein; AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK3 protein]; Arsenic Trioxide inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK3 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Sirolimus inhibits the reaction [INS protein results in increased expression of MAPK3 protein modified form]
Sirolimus affects the phosphorylation of MAPK3 protein
Sirolimus results in decreased phosphorylation of MAPK3 protein
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]]; [Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of MAPK3 protein; [Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein] which results in increased phosphorylation of MAPK3 protein; AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK3 protein]
CTD PMID:15767555, PMID:16255777, PMID:16391472, PMID:18374093, PMID:19151764, PMID:20936651, PMID:21984483, PMID:22363816, PMID:24392034, PMID:25758096, PMID:30905858 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions ISO [7-hydroxystaurosporine co-treated with Sirolimus] results in increased phosphorylation of MAPK8 protein; pyrazolanthrone inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased phosphorylation of MAPK8 protein] CTD PMID:15767555 NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
JBrowse link
G Mbnl2 muscleblind-like splicing regulator 2 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of MBNL2 mRNA] CTD PMID:21245298 NCBI chr15:105,640,097...105,797,933
Ensembl chr15:105,640,097...105,797,932
JBrowse link
G Mbp myelin basic protein increases expression ISO Sirolimus results in increased expression of MBP protein CTD PMID:20739560 NCBI chr18:79,326,738...79,437,310
Ensembl chr18:79,326,738...79,437,310
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member multiple interactions ISO [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of MCL1 protein; [Sirolimus co-treated with arsenic trioxide] results in decreased expression of MCL1 protein CTD PMID:15767555, PMID:25758096 NCBI chr 2:197,786,212...197,788,992 JBrowse link
G Mcm2 minichromosome maintenance complex component 2 multiple interactions ISO Sirolimus inhibits the reaction [IL2 protein results in increased expression of MCM2 mRNA] CTD PMID:11355896 NCBI chr 4:120,825,699...120,840,221
Ensembl chr 4:120,825,699...120,840,111
JBrowse link
G Mcm7 minichromosome maintenance complex component 7 multiple interactions ISO Sirolimus inhibits the reaction [IL2 protein results in increased expression of MCM7 mRNA] CTD PMID:11355896 NCBI chr12:19,306,615...19,313,877
Ensembl chr12:19,306,607...19,314,016
JBrowse link
G Mdm2 MDM2 proto-oncogene multiple interactions
decreases expression
ISO EIF4E protein inhibits the reaction [Sirolimus results in decreased expression of MDM2 protein]; Sirolimus inhibits the reaction [Pravastatin results in increased phosphorylation of MDM2 protein]; Sirolimus promotes the reaction [TP73 protein binds to MDM2 promoter] CTD PMID:15625077, PMID:19560264, PMID:21245298 NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
JBrowse link
G Mir122 microRNA 122 multiple interactions EXP Sirolimus inhibits the reaction [INS1 protein results in increased expression of MIR122 mRNA] CTD PMID:23920219 NCBI chr18:60,755,285...60,755,369 JBrowse link
G Mir132 microRNA 132 multiple interactions EXP Sirolimus inhibits the reaction [INS1 protein results in increased expression of MIR132 mRNA] CTD PMID:23920219 NCBI chr10:62,014,995...62,015,095
Ensembl chr10:62,014,995...62,015,095
JBrowse link
G Mir146a microRNA 146a multiple interactions ISO Sirolimus inhibits the reaction [HRAS protein mutant form results in increased expression of MIR146A mRNA] CTD PMID:30619488 NCBI chr10:28,962,476...28,962,570
Ensembl chr10:28,962,476...28,962,570
JBrowse link
G Mir151 microRNA 151 multiple interactions ISO TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR151 mRNA] CTD PMID:21245298 NCBI chr 7:114,485,547...114,485,643 JBrowse link
G Mir181a2 microRNA 181a-2 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in decreased expression of MIR181A2 mRNA] CTD PMID:21245298 NCBI chr 3:23,150,352...23,150,468
Ensembl chr 3:23,150,352...23,150,468
JBrowse link
G Mir190 microRNA 190 multiple interactions ISO TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR190A mRNA] CTD PMID:21245298 NCBI chr 8:73,030,047...73,030,131
Ensembl chr 8:73,030,047...73,030,131
JBrowse link
G Mir212 microRNA 212 multiple interactions EXP Sirolimus inhibits the reaction [INS1 protein results in increased expression of MIR212 mRNA] CTD PMID:23920219 NCBI chr10:62,014,702...62,014,812
Ensembl chr10:62,014,702...62,014,812
JBrowse link
G Mir324 microRNA 324 multiple interactions ISO TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR324 mRNA] CTD PMID:21245298 NCBI chr10:56,621,126...56,621,208
Ensembl chr10:56,621,124...56,621,212
JBrowse link
G Mir330 microRNA 330 multiple interactions ISO [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of MIR330 mRNA CTD PMID:25307878 NCBI chr 1:80,092,681...80,092,777
Ensembl chr 1:80,092,681...80,092,777
JBrowse link
G Mir433 microRNA 433 multiple interactions ISO TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR433 mRNA] CTD PMID:21245298 NCBI chr 6:133,712,334...133,712,426
Ensembl chr 6:133,712,334...133,712,426
JBrowse link
G Mir503 microRNA 503 multiple interactions ISO TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR503 mRNA] CTD PMID:21245298 NCBI chr  X:158,148,476...158,148,546
Ensembl chr  X:158,148,476...158,148,546
JBrowse link
G Mir760 microRNA 760 multiple interactions ISO TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR760 mRNA] CTD PMID:21245298 NCBI chr 2:225,873,354...225,873,433
Ensembl chr 2:225,873,354...225,873,433
JBrowse link
G Mki67 marker of proliferation Ki-67 decreases expression
affects expression
multiple interactions
ISO
EXP
Sirolimus results in decreased expression of MKI67 protein
Sirolimus affects the expression of MKI67 mRNA
[ABT-737 co-treated with Sirolimus] results in decreased expression of MKI67 protein
CTD PMID:19773376, PMID:24971338 NCBI chr 1:207,993,895...208,020,454
Ensembl chr 1:207,993,895...208,020,454
JBrowse link
G Mlst8 MTOR associated protein, LST8 homolog multiple interactions ISO Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein binds to MLST8 protein] CTD PMID:19505958 NCBI chr10:13,839,250...13,845,001
Ensembl chr10:13,839,250...13,845,001
JBrowse link
G Mmp1 matrix metallopeptidase 1 increases secretion
increases expression
ISO Sirolimus results in increased secretion of MMP1 protein
Sirolimus results in increased expression of MMP1 mRNA
CTD PMID:21742783 NCBI chr 8:5,703,206...5,723,593
Ensembl chr 8:5,703,206...5,723,591
JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions EXP Sirolimus inhibits the reaction [Thioacetamide results in increased activity of MMP2 protein] CTD PMID:17050028 NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
JBrowse link
G Mmp9 matrix metallopeptidase 9 decreases expression EXP Sirolimus results in decreased expression of MMP9 mRNA CTD PMID:21865292 NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
JBrowse link
G Mpz myelin protein zero increases expression ISO Sirolimus results in increased expression of MPZ protein CTD PMID:20739560 NCBI chr13:89,524,204...89,530,070
Ensembl chr13:89,524,329...89,530,068
JBrowse link
G Msr1 macrophage scavenger receptor 1 decreases expression ISO Sirolimus results in decreased expression of MSR1 mRNA CTD PMID:17016853 NCBI chr16:56,817,714...56,900,025
Ensembl chr16:56,813,791...56,900,052
JBrowse link
G Mtor mechanistic target of rapamycin kinase multiple interactions
increases expression
decreases expression
decreases phosphorylation
increases phosphorylation
decreases activity
increases activity
ISO
EXP
[Oxygen deficiency co-treated with Sirolimus] results in decreased expression of MTOR protein; [Sirolimus co-treated with Photosensitizing Agents] affects the phosphorylation of MTOR protein; [Sirolimus inhibits the reaction [MTOR protein binds to RPTOR protein]] which results in increased expression of MAP1LC3A protein alternative form; [Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein]] which results in increased activity of AR protein; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; [Sirolimus results in decreased activity of MTOR protein] which results in decreased expression of DDIT3 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased expression of PKM protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of EIF4EBP1 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of RPS6 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of RPS6KB1 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of TP53 protein; [Sirolimus results in decreased activity of MTOR protein] which results in increased phosphorylation of GSK3B protein; [Sirolimus results in decreased activity of MTOR protein] which results in increased susceptibility to afimoxifene; [Sirolimus results in decreased activity of MTOR protein] which results in increased susceptibility to Fulvestrant; [Sirolimus results in decreased phosphorylation of MTOR protein] which results in decreased chemical synthesis of Reactive Oxygen Species; MTOR protein inhibits the reaction [Sirolimus results in decreased activity of RPS6KB2 protein]; Sirolimus inhibits the reaction [2,4,4'-trichlorobiphenyl results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [[MTOR protein binds to RAPTOR protein] which binds to LARP1 protein]; Sirolimus inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [EGF protein results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Oxygen deficiency results in increased expression of MTOR mRNA]; Sirolimus inhibits the reaction [Palmitic Acid results in increased activity of MTOR protein]; Sirolimus inhibits the reaction [puerarin results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Serotonin results in increased activity of MTOR protein]; Sirolimus promotes the reaction [Cisplatin results in decreased phosphorylation of MTOR protein]; Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein binds to MLST8 protein]; Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein]; Sirolimus results in decreased phosphorylation of and results in increased expression of MTOR protein; sodium arsenite promotes the reaction [Sirolimus results in decreased expression of MTOR protein]
Sirolimus results in increased expression of MTOR protein modified form
Sirolimus results in decreased expression of MTOR protein; Sirolimus results in decreased expression of MTOR protein modified form
Sirolimus inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [2,2',3,5',6-pentachlorobiphenyl results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [2,4,4'-trichlorobiphenyl results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Isoproterenol results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Paraquat results in increased phosphorylation of MTOR protein]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased phosphorylation of MTOR protein]]
Sirolimus results in increased expression of MTOR mRNA
Sirolimus results in increased phosphorylation of MTOR protein
Sirolimus results in increased activity of MTOR protein
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol affects the susceptibility to Lipopolysaccharides]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased abundance of Dinoprostone]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of RELA mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of CREB1 protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]]; [Sirolimus results in decreased activity of MTOR protein] which results in decreased susceptibility to Resveratrol; Sirolimus inhibits the reaction [[Cadmium Chloride co-treated with TGFB1 protein] results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [MTOR protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of MTOR protein]
Sirolimus results in decreased expression of MTOR mRNA; Sirolimus results in decreased expression of MTOR protein; Sirolimus results in decreased expression of MTOR protein modified form
[Sirolimus results in decreased activity of MTOR protein] which results in decreased activity of RPS6KB1 protein; Sirolimus results in decreased activity of MTOR protein
CTD PMID:11602639, PMID:12087098, PMID:14673156, PMID:15050414, PMID:15782132, PMID:15919668, PMID:17623046, PMID:17908691, PMID:17968710, PMID:17996122, PMID:18058806, PMID:18381446, PMID:18640276, PMID:18776922, PMID:19016759, PMID:19125612, PMID:19151764, PMID:19505958, PMID:19567381, PMID:19698219, PMID:19815708, PMID:20169165, PMID:20368307, PMID:20680277, PMID:20682991, PMID:21168265, PMID:21187475, PMID:21321189, PMID:21450334, PMID:21742779, PMID:21898527, PMID:22069489, PMID:22363816, PMID:22561310, PMID:22574221, PMID:23111315, PMID:23363784, PMID:23958494, PMID:24971338, PMID:25045214, PMID:25576684, PMID:25884947, PMID:25940091, PMID:26201060, PMID:26282490, PMID:26648565, PMID:27107786, PMID:27133527, PMID:27324791, PMID:27796870, PMID:28342888, PMID:28888487, PMID:29518472, PMID:30132043, PMID:30236763, PMID:30555576, PMID:31051157, PMID:31499194, PMID:32044396 NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
JBrowse link
G Mturn maturin, neural progenitor differentiation regulator homolog multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of MTURN mRNA] CTD PMID:21245298 NCBI chr 4:84,854,341...84,875,300
Ensembl chr 4:84,854,386...84,871,757
JBrowse link
G Mybl2 MYB proto-oncogene like 2 multiple interactions ISO [TGFB1 protein co-treated with Sirolimus] results in decreased expression of MYBL2 protein CTD PMID:12417722 NCBI chr 3:159,421,638...159,450,087
Ensembl chr 3:159,421,671...159,450,086
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions ISO [(+)-JQ1 compound co-treated with Sirolimus] results in decreased expression of MYC protein; [(+)-JQ1 compound co-treated with Sirolimus] results in increased expression of MYC mRNA; [Sirolimus co-treated with letrozole] results in decreased expression of MYC protein CTD PMID:20054642, PMID:25307878 NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
JBrowse link
G Mydgf myeloid-derived growth factor decreases expression ISO Sirolimus decreases expression of Mydgf mRNA in enterocytes RGD PMID:28717211 RGD:39456117 NCBI chr 9:10,885,521...10,892,744
Ensembl chr 9:10,885,560...10,892,405
JBrowse link
G Myf5 myogenic factor 5 decreases expression ISO Sirolimus results in decreased expression of MYF5 protein CTD PMID:30905858 NCBI chr 7:49,729,533...49,732,974
Ensembl chr 7:49,729,533...49,732,764
JBrowse link
G Myh11 myosin heavy chain 11 multiple interactions
increases expression
ISO [Sirolimus co-treated with IGF1 protein] results in increased expression of MYH11 protein; [Sirolimus results in increased activity of AKT2 protein] which results in increased expression of MYH11 protein
Sirolimus results in increased expression of MYH11 protein
CTD PMID:17908691 NCBI chr10:764,421...859,184
Ensembl chr10:764,421...859,184
JBrowse link
G Myh7 myosin heavy chain 7 multiple interactions EXP Sirolimus inhibits the reaction [Isoproterenol results in increased expression of MYH7 mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of MYH7 mRNA]] CTD PMID:25045214 NCBI chr15:33,605,769...33,657,761
Ensembl chr15:33,634,422...33,656,089
JBrowse link
G Mylk myosin light chain kinase multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of MYLK mRNA] CTD PMID:21245298 NCBI chr11:69,013,060...69,260,039
Ensembl chr11:69,013,050...69,223,158
JBrowse link
G Myod1 myogenic differentiation 1 affects expression ISO Sirolimus affects the expression of MYOD1 protein CTD PMID:30905858 NCBI chr 1:102,396,538...102,399,248
Ensembl chr 1:102,396,538...102,399,248
JBrowse link
G Myof myoferlin multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of MYOF mRNA] CTD PMID:21245298 NCBI chr 1:256,585,410...256,734,727
Ensembl chr 1:256,585,410...256,734,730
JBrowse link
G Naip6 NLR family, apoptosis inhibitory protein 6 decreases expression ISO Sirolimus results in decreased expression of NAIP mRNA CTD PMID:9836529 NCBI chr 2:30,377,505...30,418,578 JBrowse link
G Nanog Nanog homeobox increases expression ISO Sirolimus results in increased expression of NANOG mRNA CTD PMID:21681844 NCBI chr 4:155,531,906...155,539,268
Ensembl chr 4:155,531,906...155,539,268
JBrowse link
G Ncf1 neutrophil cytosolic factor 1 multiple interactions
decreases expression
EXP Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of NCF1 protein]
Sirolimus results in decreased expression of NCF1 protein
CTD PMID:21195169 NCBI chr12:25,497,104...25,506,300
Ensembl chr12:25,497,104...25,506,300
JBrowse link
G Ncf2 neutrophil cytosolic factor 2 decreases expression
multiple interactions
EXP Sirolimus results in decreased expression of NCF2 protein
Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of NCF2 protein]
CTD PMID:21195169 NCBI chr13:70,226,441...70,259,019
Ensembl chr13:70,226,647...70,257,576
JBrowse link
G Ncf4 neutrophil cytosolic factor 4 multiple interactions EXP Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of NCF4 protein] CTD PMID:21195169 NCBI chr 7:119,481,711...119,499,426
Ensembl chr 7:119,482,272...119,499,425
JBrowse link
G Ndc80 NDC80 kinetochore complex component multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of NDC80 mRNA CTD PMID:19016759 NCBI chr 9:119,837,857...119,871,435
Ensembl chr 9:119,839,016...119,871,382
JBrowse link
G Nek2 NIMA-related kinase 2 multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of NEK2 mRNA CTD PMID:19016759 NCBI chr13:110,511,546...110,524,750
Ensembl chr13:110,511,668...110,522,769
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 multiple interactions
increases activity
EXP
ISO
NFE2L2 protein promotes the reaction [Sirolimus inhibits the reaction [Paraquat results in decreased expression of CDH1 protein]]; NFE2L2 protein promotes the reaction [Sirolimus inhibits the reaction [Paraquat results in increased expression of SNAI1 protein]]; NFE2L2 protein promotes the reaction [Sirolimus inhibits the reaction [Paraquat results in increased expression of VIM protein]]; Sirolimus inhibits the reaction [Paraquat results in decreased expression of NFE2L2 mRNA]; Sirolimus inhibits the reaction [Paraquat results in decreased expression of NFE2L2 protein]
Sirolimus results in increased activity of NFE2L2 protein
CTD PMID:28624451, PMID:30203046 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions ISO Sirolimus inhibits the reaction [Doxorubicin results in increased activity of NFKB1 protein] CTD PMID:15571967 NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO
EXP
Sirolimus inhibits the reaction [Doxorubicin results in increased degradation of and results in decreased expression of NFKBIA protein]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]
Sirolimus inhibits the reaction [Isoproterenol results in increased degradation of NFKBIA protein]; Sirolimus inhibits the reaction [Pilocarpine results in increased phosphorylation of NFKBIA protein]
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]
CTD PMID:15571967, PMID:18789402, PMID:22363816, PMID:23211629, PMID:25045214 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 multiple interactions
decreases expression
ISO Sirolimus inhibits the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased expression of NLRP3 protein]
Sirolimus results in decreased expression of NLRP3 protein
CTD PMID:30205151, PMID:32645460 NCBI chr10:45,884,324...45,918,290
Ensembl chr10:45,893,018...45,918,254
JBrowse link
G Nme1 NME/NM23 nucleoside diphosphate kinase 1 multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of NME1 mRNA CTD PMID:19016759 NCBI chr10:81,657,152...81,666,542
Ensembl chr10:81,657,153...81,666,523
JBrowse link
G Nmu neuromedin U multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of NMU mRNA] CTD PMID:21245298 NCBI chr14:34,353,683...34,381,968
Ensembl chr14:34,354,503...34,381,828
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO
EXP
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Sirolimus inhibits the reaction [Ethylene Chlorohydrin promotes the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]]
Sirolimus inhibits the reaction [Pilocarpine results in increased expression of NOS2 mRNA]; Sirolimus inhibits the reaction [Pilocarpine results in increased expression of NOS2 protein]
CTD PMID:22363816, PMID:23211629, PMID:31499194 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Nos3 nitric oxide synthase 3 multiple interactions
increases phosphorylation
decreases expression
ISO Aspirin inhibits the reaction [Sirolimus results in decreased expression of NOS3 protein]; cilostazol inhibits the reaction [Sirolimus results in decreased expression of NOS3 protein]
Sirolimus results in increased phosphorylation of NOS3 protein
Sirolimus results in decreased expression of NOS3 mRNA; Sirolimus results in decreased expression of NOS3 protein
CTD PMID:17261647, PMID:19520256, PMID:19815708 NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
JBrowse link
G Notch1 notch receptor 1 affects expression EXP Sirolimus affects the expression of NOTCH1 protein CTD PMID:26676567 NCBI chr 3:3,905,562...3,951,015
Ensembl chr 3:3,905,453...3,951,025
JBrowse link
G Nphs2 NPHS2 stomatin family member, podocin affects expression EXP Sirolimus affects the expression of NPHS2 protein CTD PMID:19671594 NCBI chr13:73,929,136...73,941,522
Ensembl chr13:73,929,136...73,941,522
JBrowse link
G Nppa natriuretic peptide A multiple interactions EXP Sirolimus inhibits the reaction [Isoproterenol results in increased expression of NPPA mRNA]; Sirolimus inhibits the reaction [rosiglitazone results in increased expression of NPPA mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of NPPA mRNA]] CTD PMID:19397913, PMID:25045214 NCBI chr 5:164,808,407...164,809,716
Ensembl chr 5:164,808,323...164,809,705
JBrowse link
G Nppb natriuretic peptide B multiple interactions EXP Sirolimus inhibits the reaction [Isoproterenol results in increased expression of NPPB mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of NPPB mRNA]] CTD PMID:25045214 NCBI chr 5:164,796,176...164,797,538
Ensembl chr 5:164,796,185...164,797,531
JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 affects expression ISO Sirolimus affects the expression of NR1H3 protein CTD PMID:17016853 NCBI chr 3:80,004,130...80,014,197
Ensembl chr 3:80,004,130...80,012,750
JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in decreased expression of NR1H4 mRNA] CTD PMID:21245298 NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
JBrowse link
G Nr3c1 nuclear receptor subfamily 3, group C, member 1 increases activity ISO Sirolimus results in increased activity of NR3C1 protein CTD PMID:15697228 NCBI chr18:31,728,373...32,704,022
Ensembl chr18:31,728,373...31,749,647
JBrowse link
G Nr5a1 nuclear receptor subfamily 5, group A, member 1 multiple interactions ISO Sirolimus inhibits the reaction [Ethanol results in decreased expression of NR5A1 protein] CTD PMID:29524503 NCBI chr 3:22,998,900...23,020,441
Ensembl chr 3:22,999,616...23,020,441
JBrowse link
G Nxt1 nuclear transport factor 2-like export factor 1 decreases expression ISO Sirolimus results in decreased expression of NXT1 mRNA CTD PMID:11355896 NCBI chr 3:142,993,658...142,996,580
Ensembl chr 3:142,993,658...142,996,578
JBrowse link
G Ogn osteoglycin increases expression EXP Sirolimus results in increased expression of OGN mRNA CTD PMID:21865292 NCBI chr17:14,607,442...14,628,274
Ensembl chr17:15,447,716...15,467,359
Ensembl chr17:15,447,716...15,467,359
JBrowse link
G Olr1 oxidized low density lipoprotein receptor 1 affects expression ISO Sirolimus affects the expression of OLR1 protein CTD PMID:17016853 NCBI chr 4:163,239,853...163,261,937
Ensembl chr 4:163,239,849...163,261,958
JBrowse link
G Optn optineurin multiple interactions ISO Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of OPTN protein] CTD PMID:25884947 NCBI chr17:77,167,700...77,218,374
Ensembl chr17:77,167,740...77,218,389
JBrowse link
G Oxa1l OXA1L, mitochondrial inner membrane protein multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of OXA1L mRNA] CTD PMID:21245298 NCBI chr15:33,004,957...33,012,584
Ensembl chr15:33,004,133...33,012,575
JBrowse link
G Pabpc1 poly(A) binding protein, cytoplasmic 1 multiple interactions
decreases expression
ISO Sirolimus inhibits the reaction [EIF4G1 protein binds to PABPC1 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to PABPC1 mRNA]
Sirolimus results in decreased expression of PABPC1 protein
CTD PMID:25940091 NCBI chr 7:75,409,581...75,421,874
Ensembl chr 7:75,409,581...75,422,268
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases expression
increases cleavage
ISO
EXP
ATG5 protein affects the reaction [Sirolimus inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein]]; Sirolimus inhibits the reaction [Ethanol results in increased cleavage of PARP1 protein]; Sirolimus inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein]
Sirolimus promotes the reaction [Cadmium results in increased cleavage of PARP1 protein]
[Sirolimus co-treated with Resveratrol] results in increased cleavage of PARP1 protein; TSC2 protein inhibits the reaction [[Sirolimus co-treated with Resveratrol] results in increased cleavage of PARP1 protein]
Sirolimus results in increased expression of PARP1 protein modified form
Sirolimus results in increased cleavage of PARP1 protein
CTD PMID:19682553, PMID:21410490, PMID:24304514, PMID:25307878, PMID:26825372, PMID:29111403 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Pax8 paired box 8 multiple interactions ISO Sirolimus promotes the reaction [TP73 protein affects the activity of PAX8 protein] CTD PMID:21245298 NCBI chr 3:1,527,316...1,586,019
Ensembl chr 3:1,527,279...1,584,946
JBrowse link
G Pck1 phosphoenolpyruvate carboxykinase 1 multiple interactions EXP [troglitazone co-treated with Sirolimus] results in decreased expression of PCK1 mRNA CTD PMID:10446394 NCBI chr 3:171,213,936...171,219,885
Ensembl chr 3:171,213,936...171,219,871
JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions
decreases expression
ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of PCNA mRNA
Sirolimus inhibits the reaction [IL2 protein results in increased expression of PCNA mRNA]
Sirolimus results in decreased expression of PCNA protein
CTD PMID:9151781, PMID:11355896, PMID:19016759 NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
JBrowse link
G Pdcd4 programmed cell death 4 multiple interactions
increases stability
increases expression
ISO
EXP
[resveratrol co-treated with Sirolimus] results in increased stability of PDCD4 protein; Sirolimus promotes the reaction [Tretinoin results in increased expression of PDCD4 protein]
Sirolimus results in increased stability of PDCD4 protein
resveratrol inhibits the reaction [Sirolimus results in increased stability of PDCD4 protein]
[Sirolimus co-treated with resveratrol] results in increased stability of PDCD4 protein; PDCD4 mutant form inhibits the reaction [Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased expression of CTSK mRNA]]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in decreased expression of PDCD4 mRNA]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in decreased expression of PDCD4 protein]; TSC2 gene mutant form promotes the reaction [[Sirolimus co-treated with resveratrol] results in increased stability of PDCD4 protein]
Sirolimus results in increased expression of PDCD4 protein
Sirolimus results in increased expression of PDCD4 mRNA; Sirolimus results in increased expression of PDCD4 protein
CTD PMID:17259349, PMID:24304514, PMID:24356939, PMID:26369790 NCBI chr 1:274,616,625...274,648,204
Ensembl chr 1:274,625,224...274,648,204
JBrowse link
G Pdgfb platelet derived growth factor subunit B multiple interactions ISO [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein] CTD PMID:15919668 NCBI chr 7:121,215,458...121,233,092
Ensembl chr 7:121,214,628...121,232,741
JBrowse link
G Pik3ca phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha decreases response to substance
increases activity
multiple interactions
ISO Sirolimus results in decreased susceptibility to PIK3CA protein
Sirolimus results in increased activity of PIK3CA protein
Sirolimus inhibits the reaction [PIK3CA protein modified form results in decreased expression of CCNG2 mRNA]; Sirolimus inhibits the reaction [PIK3CA protein modified form results in decreased expression of CXCL8 mRNA]; Sirolimus inhibits the reaction [PIK3CA protein modified form results in decreased expression of HBP1 mRNA]; Sirolimus inhibits the reaction [PIK3CA protein modified form results in increased expression of CCNE2 mRNA]; Sirolimus inhibits the reaction [PIK3CA protein modified form results in increased expression of PPP2R1B mRNA]; Wortmannin inhibits the reaction [Sirolimus results in increased activity of PIK3CA protein]
CTD PMID:10373522, PMID:16227402, PMID:27542212 NCBI chr 2:118,831,350...118,861,456
Ensembl chr 2:118,831,350...118,861,454
JBrowse link
G Pik3r1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions ISO Sirolimus promotes the reaction [IRS1 protein binds to PIK3R1 protein] CTD PMID:17908691 NCBI chr 2:31,742,326...31,826,882
Ensembl chr 2:31,745,088...31,826,867
JBrowse link
G Pim1 Pim-1 proto-oncogene, serine/threonine kinase multiple interactions ISO [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of PIM1 mRNA CTD PMID:25307878 NCBI chr20:8,165,423...8,169,557
Ensembl chr20:8,165,307...8,169,555
JBrowse link
G Pkm pyruvate kinase M1/2 multiple interactions ISO [Sirolimus results in decreased activity of MTOR protein] which results in decreased expression of PKM protein CTD PMID:22574221 NCBI chr 8:64,480,963...64,502,957
Ensembl chr 8:64,481,172...64,502,722
JBrowse link
G Pkp4 plakophilin 4 increases expression EXP Sirolimus results in increased expression of PKP4 mRNA CTD PMID:21865292 NCBI chr 3:45,211,097...45,414,524
Ensembl chr 3:45,277,348...45,414,613
JBrowse link
G Plcl1 phospholipase C-like 1 increases expression ISO Sirolimus results in increased expression of PLCL1 mRNA CTD PMID:24356939 NCBI chr 9:62,016,112...62,349,244
Ensembl chr 9:62,291,405...62,349,309
JBrowse link
G Pmaip1 phorbol-12-myristate-13-acetate-induced protein 1 multiple interactions ISO [[Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein] which results in increased expression of PMAIP1 protein CTD PMID:20686837 NCBI chr18:62,159,128...62,179,635
Ensembl chr18:62,174,670...62,181,102
JBrowse link
G Pml PML nuclear body scaffold increases expression
increases localization
decreases response to substance
ISO Sirolimus results in increased expression of PML protein
Sirolimus results in increased localization of PML protein
PML protein results in decreased susceptibility to Sirolimus
CTD PMID:23440206 NCBI chr 8:63,002,515...63,034,310
Ensembl chr 8:63,004,870...63,034,226
JBrowse link
G Pmp22 peripheral myelin protein 22 increases metabolic processing ISO Sirolimus results in increased metabolism of PMP22 protein mutant form CTD PMID:20739560 NCBI chr10:49,538,588...49,568,583
Ensembl chr10:49,538,588...49,568,583
JBrowse link
G Pnpla2 patatin-like phospholipase domain containing 2 increases expression ISO Sirolimus results in increased expression of PNPLA2 mRNA; Sirolimus results in increased expression of PNPLA2 protein CTD PMID:20068142 NCBI chr 1:214,434,638...214,439,720
Ensembl chr 1:214,434,626...214,439,720
JBrowse link
G Pnrc1 proline-rich nuclear receptor coactivator 1 increases expression ISO Sirolimus results in increased expression of PNRC1 mRNA CTD PMID:24356939 NCBI chr 5:48,501,472...48,504,511
Ensembl chr 5:48,501,472...48,504,511
JBrowse link
G Pold2 DNA polymerase delta 2, accessory subunit decreases expression ISO Sirolimus results in decreased expression of POLD2 mRNA CTD PMID:11355896 NCBI chr14:86,111,416...86,117,578
Ensembl chr14:86,111,294...86,117,578
JBrowse link
G Polr1h RNA polymerase I subunit H multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of POLR1H mRNA] CTD PMID:21245298 NCBI chr20:2,088,518...2,092,436
Ensembl chr20:2,088,533...2,092,436
JBrowse link
G Postn periostin multiple interactions EXP Sirolimus inhibits the reaction [FGF1 protein results in increased expression of POSTN mRNA] CTD PMID:15121739 NCBI chr 2:143,656,820...143,688,087
Ensembl chr 2:143,656,793...143,688,087
JBrowse link
G Pou5f1 POU class 5 homeobox 1 increases expression ISO Sirolimus results in increased expression of POU5F1 mRNA; Sirolimus results in increased expression of POU5F1 protein CTD PMID:21681844 NCBI chr20:3,747,231...3,751,994
Ensembl chr20:3,747,221...3,751,994
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions EXP Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARA mRNA]; Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARA protein]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARA mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARA protein]] CTD PMID:25045214 NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
JBrowse link
G Ppard peroxisome proliferator-activated receptor delta multiple interactions ISO PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of ERN1 protein]; PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of HSPA5 protein] CTD PMID:24898257 NCBI chr20:7,818,289...7,883,482
Ensembl chr20:7,818,289...7,885,333
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma affects expression
decreases expression
multiple interactions
ISO Sirolimus affects the expression of PPARG protein
Sirolimus results in decreased expression of PPARG mRNA
[Sirolimus co-treated with Cyclosporine] results in decreased expression of PPARG protein; [Sirolimus co-treated with Tacrolimus] results in increased expression of PPARG protein
CTD PMID:15358118, PMID:17016853 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
G Ppargc1a PPARG coactivator 1 alpha multiple interactions EXP
ISO
Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARGC1A mRNA]; Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARGC1A protein]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARGC1A mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARGC1A protein]]
Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in increased expression of PPARGC1A mRNA]
CTD PMID:25045214, PMID:31499194 NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
JBrowse link
G Ppl periplakin increases expression EXP Sirolimus results in increased expression of PPL mRNA CTD PMID:21865292 NCBI chr10:10,644,572...10,690,223
Ensembl chr10:10,644,572...10,690,223
JBrowse link
G Ppp1r1b protein phosphatase 1, regulatory (inhibitor) subunit 1B multiple interactions ISO Sirolimus inhibits the reaction [BDNF protein results in increased expression of PPP1R1B mRNA]; Sirolimus inhibits the reaction [BDNF protein results in increased expression of PPP1R1B protein] CTD PMID:17209049 NCBI chr10:86,303,727...86,312,770
Ensembl chr10:86,303,727...86,312,762
JBrowse link
G Ppp2r1b protein phosphatase 2 scaffold subunit A beta multiple interactions ISO Sirolimus inhibits the reaction [PIK3CA protein modified form results in increased expression of PPP2R1B mRNA] CTD PMID:27542212 NCBI chr 8:55,279,278...55,311,768
Ensembl chr 8:55,279,373...55,301,320
JBrowse link
G Prcp prolylcarboxypeptidase increases expression EXP Sirolimus results in increased expression of PRCP mRNA CTD PMID:21865292 NCBI chr 1:157,701,089...157,750,177
Ensembl chr 1:157,701,089...157,750,169
JBrowse link
G Prf1 perforin 1 decreases expression ISO Sirolimus results in decreased expression of PRF1 protein CTD PMID:16477233 NCBI chr20:30,915,294...30,920,804
Ensembl chr20:30,915,213...30,921,382
JBrowse link
G Prkaa1 protein kinase AMP-activated catalytic subunit alpha 1 multiple interactions EXP Sirolimus inhibits the reaction [Cadmium Chloride results in decreased phosphorylation of PRKAA1 protein] CTD PMID:21195169 NCBI chr 2:54,857,688...54,893,404
Ensembl chr 2:54,857,688...54,893,404
JBrowse link
G Prkca protein kinase C, alpha multiple interactions ISO Sirolimus inhibits the reaction [Estradiol results in increased phosphorylation of PRKCA protein] CTD PMID:23000059 NCBI chr10:96,186,509...96,585,168
Ensembl chr10:96,191,133...96,584,947
JBrowse link
G Prkcd protein kinase C, delta affects localization
multiple interactions
decreases phosphorylation
ISO Sirolimus affects the localization of PRKCD protein
sodium arsenite promotes the reaction [Sirolimus results in decreased phosphorylation of PRKCD protein]
CTD PMID:20082316 NCBI chr16:6,655,131...6,675,746
Ensembl chr16:6,655,120...6,675,746
JBrowse link
G Prkcg protein kinase C, gamma increases degradation
multiple interactions
ISO Sirolimus results in increased degradation of PRKCG protein mutant form
Sirolimus inhibits the reaction [PRKCG protein mutant form binds to PRKCG protein mutant form]
CTD PMID:20398063 NCBI chr 1:64,407,098...64,433,698
Ensembl chr 1:64,407,114...64,433,636
JBrowse link
G Prkch protein kinase C, eta decreases response to substance
multiple interactions
ISO PRKCH results in decreased susceptibility to Sirolimus
[Tetradecanoylphorbol Acetate results in increased activity of PRKCH protein] inhibits the reaction [Sirolimus results in decreased phosphorylation of RPS6 protein]
CTD PMID:16832347 NCBI chr 6:96,479,243...96,677,368
Ensembl chr 6:96,479,430...96,676,225
JBrowse link
G Prlr prolactin receptor decreases expression EXP Sirolimus results in decreased expression of PRLR mRNA CTD PMID:21865292 NCBI chr 2:60,131,410...60,325,686
Ensembl chr 2:60,131,776...60,325,692
JBrowse link
G Psma1 proteasome 20S subunit alpha 1 decreases expression ISO Sirolimus results in decreased expression of PSMA1 mRNA CTD PMID:11355896 NCBI chr 1:183,733,567...183,744,586
Ensembl chr 1:183,733,567...183,744,586
JBrowse link
G Psma4 proteasome 20S subunit alpha 4 decreases expression ISO Sirolimus results in decreased expression of PSMA4 mRNA CTD PMID:11355896 NCBI chr 8:59,532,456...59,539,916
Ensembl chr 8:59,532,389...59,539,920
JBrowse link
G Psmd11 proteasome 26S subunit, non-ATPase 11 decreases expression ISO Sirolimus results in decreased expression of PSMD11 mRNA; Sirolimus results in decreased expression of PSMD11 protein CTD PMID:15782132 NCBI chr10:67,810,655...67,857,562
Ensembl chr10:67,810,655...67,857,223
JBrowse link
G Pten phosphatase and tensin homolog multiple interactions
decreases expression
decreases response to substance
ISO
EXP
[Decitabine co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Sirolimus] results in increased expression of PTEN mRNA; Sirolimus inhibits the reaction [TNF protein results in decreased expression of PTEN protein]
Sirolimus inhibits the reaction [Cadmium Chloride results in decreased expression of PTEN protein]
Sirolimus results in decreased expression of PTEN protein
PTEN protein results in decreased susceptibility to Sirolimus
CTD PMID:18303120, PMID:18622747, PMID:19625624, PMID:21195169, PMID:31676321 NCBI chr 1:251,421,814...251,487,634
Ensembl chr 1:251,421,596...251,487,832
JBrowse link
G Ptger1 prostaglandin E receptor 1 multiple interactions ISO Sirolimus inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein] CTD PMID:20335389 NCBI chr19:24,799,422...24,803,373
Ensembl chr19:24,800,072...24,803,373
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions
affects expression
ISO
EXP
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]]
Sirolimus affects the expression of PTGS2 mRNA
Sirolimus inhibits the reaction [Pilocarpine results in increased expression of PTGS2 mRNA]; Sirolimus inhibits the reaction [Pilocarpine results in increased expression of PTGS2 protein]
CTD PMID:22363816, PMID:23211629, PMID:24971338 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Ptk2 protein tyrosine kinase 2 decreases phosphorylation ISO Sirolimus results in decreased phosphorylation of PTK2 protein CTD PMID:19922502 NCBI chr 7:114,436,419...114,611,317
Ensembl chr 7:114,437,361...114,590,119
JBrowse link
G Ptpn5 protein tyrosine phosphatase, non-receptor type 5 multiple interactions EXP Sirolimus inhibits the reaction [Isoproterenol results in increased expression of PTPN5 protein] CTD PMID:17623046 NCBI chr 1:103,197,918...103,258,309
Ensembl chr 1:103,197,915...103,256,823
JBrowse link
G Ptprc protein tyrosine phosphatase, receptor type, C increases expression ISO Sirolimus results in increased expression of PTPRC mRNA CTD PMID:11355896 NCBI chr13:55,061,561...55,174,150
Ensembl chr13:55,061,562...55,173,692
JBrowse link
G Pttg1 PTTG1 regulator of sister chromatid separation, securin multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of PTTG1 mRNA CTD PMID:19016759 NCBI chr10:29,014,332...29,026,088
Ensembl chr10:29,020,049...29,026,002
JBrowse link
G Rac1 Rac family small GTPase 1 decreases expression
multiple interactions
EXP Sirolimus results in decreased expression of RAC1 protein
Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of RAC1 protein]
CTD PMID:21195169 NCBI chr12:13,090,316...13,111,841
Ensembl chr12:13,090,172...13,111,873
JBrowse link
G Rad51 RAD51 recombinase multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of RAD51 mRNA CTD PMID:19016759 NCBI chr 3:110,918,240...110,942,920
Ensembl chr 3:110,918,243...110,942,917
JBrowse link
G Raf1 Raf-1 proto-oncogene, serine/threonine kinase multiple interactions ISO [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of RAF1 protein CTD PMID:15767555 NCBI chr 4:147,532,040...147,592,769
Ensembl chr 4:147,532,042...147,592,699
JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions
decreases phosphorylation
ISO
EXP
[Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased phosphorylation of RB1 protein]; [Sirolimus co-treated with Letrozole] results in decreased expression of RB1 protein; [Sirolimus co-treated with TGFB1 protein] results in decreased phosphorylation of RB1 protein; [tanespimycin co-treated with Sirolimus] results in decreased phosphorylation of RB1 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of RB1 protein; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RB1 protein]
Sirolimus results in decreased phosphorylation of RB1 protein
[Sirolimus co-treated with TGFB1 protein] results in decreased phosphorylation of RB1 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of RB1 protein; Sirolimus inhibits the reaction [KITL protein results in increased phosphorylation of RB1 protein]
CTD PMID:7532117, PMID:8419408, PMID:10373522, PMID:10849422, PMID:12393642, PMID:12417722, PMID:12565877, PMID:14979923, PMID:15753396, PMID:15778701, PMID:17121904, PMID:17700525, PMID:20054642, PMID:21528311 NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
JBrowse link
G Rbl1 RB transcriptional corepressor like 1 multiple interactions ISO [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL1 protein] which binds to CDK2 protein] CTD PMID:12417722 NCBI chr 3:153,263,692...153,321,351
Ensembl chr 3:153,263,692...153,321,352
JBrowse link
G Rbl2 RB transcriptional corepressor like 2 multiple interactions ISO [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL2 protein] which binds to CDK2 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RBL2 protein] CTD PMID:10373522, PMID:12417722 NCBI chr19:17,300,088...17,346,865
Ensembl chr19:17,300,089...17,346,808
JBrowse link
G Rcan1 regulator of calcineurin 1 multiple interactions ISO [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of RCAN1 mRNA CTD PMID:25307878 NCBI chr11:32,539,689...32,620,274
Ensembl chr11:32,539,683...32,550,539
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO
EXP
Sirolimus inhibits the reaction [Doxorubicin results in increased activity of RELA protein]; Sirolimus inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein]
Sirolimus inhibits the reaction [Isoproterenol affects the localization of RELA protein]; Sirolimus inhibits the reaction [Zearalenone results in increased phosphorylation of and affects the localization of RELA protein]
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of RELA mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]]; Sirolimus inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]
CTD PMID:15571967, PMID:18789402, PMID:22003094, PMID:22363816, PMID:25045214, PMID:31586597 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Ren renin increases expression EXP Sirolimus results in increased expression of REN mRNA CTD PMID:21865292 NCBI chr13:50,502,724...50,513,953
Ensembl chr13:50,502,724...50,514,151
JBrowse link
G Rest RE1-silencing transcription factor multiple interactions ISO Sirolimus promotes the reaction [TP73 protein affects the activity of REST protein] CTD PMID:21245298 NCBI chr14:33,131,985...33,152,019
Ensembl chr14:33,134,511...33,164,141
JBrowse link
G Rictor RPTOR independent companion of MTOR, complex 2 decreases expression ISO Sirolimus results in decreased expression of RICTOR protein CTD PMID:18776922 NCBI chr 2:56,013,898...56,105,818
Ensembl chr 2:56,052,643...56,101,803
JBrowse link
G Rpl32 ribosomal protein L32 multiple interactions
decreases expression
ISO LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPL32 protein]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPL32 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to RPL32 mRNA] CTD PMID:25940091 NCBI chr 4:147,715,480...147,719,044
Ensembl chr 6:145,777,318...145,777,767
Ensembl chr 4:145,777,318...145,777,767
JBrowse link
G Rps20 ribosomal protein S20 multiple interactions
decreases expression
ISO LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPS20 protein]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPS20 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to RPS20 mRNA] CTD PMID:25940091 NCBI chr 5:16,706,052...16,707,214
Ensembl chr 5:16,706,082...16,706,909
JBrowse link
G Rps27l ribosomal protein S27-like multiple interactions ISO Sirolimus promotes the reaction [TP73 protein binds to RPS27L promoter] CTD PMID:21245298 NCBI chr 8:72,741,155...72,746,090
Ensembl chr 8:72,741,155...72,746,090
JBrowse link
G Rps6 ribosomal protein S6 multiple interactions
decreases phosphorylation
increases phosphorylation
decreases expression
ISO
EXP
[Resveratrol co-treated with Sirolimus] results in decreased phosphorylation of RPS6 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of RPS6 protein; [Tetradecanoylphorbol Acetate results in increased activity of PRKCH protein] inhibits the reaction [Sirolimus results in decreased phosphorylation of RPS6 protein]; LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPS6 protein]; Sirolimus inhibits the reaction [CXCL8 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPS6 mRNA]; Sirolimus inhibits the reaction [HRAS protein mutant form results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [INS protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [Testosterone results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6 protein]; Sirolimus promotes the reaction [LARP1 protein binds to RPS6 mRNA]; TSC2 gene mutant form promotes the reaction [[Resveratrol co-treated with Sirolimus] results in decreased phosphorylation of RPS6 protein]; TSC2 gene mutant form promotes the reaction [Sirolimus results in decreased phosphorylation of RPS6 protein]
[resveratrol co-treated with Sirolimus] results in decreased phosphorylation of RPS6 protein
Sirolimus results in increased phosphorylation of RPS6 protein
[Resveratrol co-treated with Sirolimus] results in decreased phosphorylation of RPS6 protein; Sirolimus inhibits the reaction [[Cadmium Chloride co-treated with TGFB1 protein] results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [CSF1 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [TNFSF11 protein results in increased phosphorylation of RPS6 protein]; Tacrolimus inhibits the reaction [Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]]
CTD PMID:1614535, PMID:10373522, PMID:12939469, PMID:14502240, PMID:15297429, PMID:15778701, PMID:16832347, PMID:17121904, PMID:17606477, PMID:17908691, PMID:19478560, PMID:19625624, PMID:20038814, PMID:20068142, PMID:20169165, PMID:20863555, PMID:21036700, PMID:21212465, PMID:21245298, PMID:21450334, PMID:22069489, PMID:23363784, PMID:23440206, PMID:24304514, PMID:24375594, PMID:24386346, PMID:24392034, PMID:25940091, PMID:26621329, PMID:27255535, PMID:28342888, PMID:28574600, PMID:28790194, PMID:29793971, PMID:30619488, PMID:31051157, PMID:31676321 NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
JBrowse link
G Rps6ka1 ribosomal protein S6 kinase A1 increases phosphorylation
multiple interactions
affects localization
ISO
EXP
Sirolimus results in increased phosphorylation of RPS6KA1 protein
Sirolimus results in increased phosphorylation of and results in increased activity of RPS6KA1 protein
Sirolimus affects the localization of RPS6KA1 protein
CTD PMID:19151764 NCBI chr 5:152,078,217...152,122,684
Ensembl chr 5:152,078,220...152,122,684
JBrowse link
G Rps6ka2 ribosomal protein S6 kinase A2 affects localization
increases phosphorylation
ISO Sirolimus affects the localization of RPS6KA2 protein
Sirolimus results in increased phosphorylation of RPS6KA2 protein
CTD PMID:19151764 NCBI chr 1:53,219,346...53,499,445
Ensembl chr 1:53,360,157...53,499,445
JBrowse link
G Rps6ka3 ribosomal protein S6 kinase A3 affects localization
increases phosphorylation
ISO Sirolimus affects the localization of RPS6KA3 protein
Sirolimus results in increased phosphorylation of RPS6KA3 protein
CTD PMID:19151764 NCBI chr  X:37,469,736...37,576,055
Ensembl chr  X:37,469,937...37,575,624
JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 multiple interactions
increases expression
decreases phosphorylation
increases phosphorylation
decreases expression
decreases activity
ISO
EXP
[Dexamethasone co-treated with Sirolimus] inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6KB1 protein]; [Dexamethasone co-treated with Sirolimus] inhibits the reaction [IL6 protein results in increased phosphorylation of RPS6KB1 protein]; [Resveratrol co-treated with Sirolimus] results in increased phosphorylation of RPS6KB1 protein; [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of RPS6KB1 protein; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of RPS6KB1 protein; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in decreased abundance of Superoxides; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased abundance of Nitric Oxide; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased activity of IRS1 protein; Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Acetaldehyde results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [arsenite results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [cyanoginosin LR promotes the reaction [INS protein results in increased expression of RPS6KB1 protein modified form]]; Sirolimus inhibits the reaction [cyanoginosin LR results in increased expression of RPS6KB1 protein modified form]; Sirolimus inhibits the reaction [cyanoginosin LR results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [INS protein promotes the reaction [cyanoginosin LR results in increased expression of RPS6KB1 protein modified form]]; Sirolimus inhibits the reaction [INS protein results in increased expression of RPS6KB1 protein modified form]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Orotic Acid results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [oxophenylarsine results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [puerarin results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Testosterone results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased phosphorylation of RPS6KB1 protein]; Sirolimus promotes the reaction [sodium arsenite results in decreased phosphorylation of RPS6KB1 protein]; Sirolimus results in decreased phosphorylation of and results in decreased activity of RPS6KB1 protein; sodium arsenite promotes the reaction [Sirolimus results in decreased phosphorylation of RPS6KB1 protein]
Sirolimus results in increased expression of RPS6KB1 protein modified form
Sirolimus results in increased phosphorylation of RPS6KB1 protein
Sirolimus results in decreased expression of RPS6KB1 protein modified form
Sirolimus results in decreased phosphorylation of RPS6KB1 protein; Sirolimus results in decreased phosphorylation of S6K protein
[Sirolimus co-treated with Resveratrol] inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of RPS6KB1 protein]; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BAX mRNA; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BAX protein; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BID mRNA; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BID protein; MRK 003 promotes the reaction [Sirolimus results in decreased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [arsenite results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [arsenite results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [INS1 protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [MTOR protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Propranolol results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [TSC1 gene mutant form results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of RPS6KB1 protein modified form]; Sirolimus promotes the reaction [MRK 003 results in decreased activity of RPS6KB1 protein]; Sirolimus promotes the reaction [Resveratrol results in decreased phosphorylation of RPS6KB1 protein]
[Sirolimus co-treated with Resveratrol] results in decreased phosphorylation of RPS6KB1 protein; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Cadmium results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [EDN1 protein results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [INS1 protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [MAP2K1 protein results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [Phenylephrine results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [Resveratrol inhibits the reaction [TSC2 protein results in decreased phosphorylation of RPS6KB1 protein]]; Sirolimus inhibits the reaction [Sertraline results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus results in decreased phosphorylation of and results in decreased activity of RPS6KB1 protein
[Sirolimus results in decreased activity of MTOR protein] which results in decreased activity of RPS6KB1 protein; Sirolimus results in decreased activity of RPS6KB1 protein
CTD PMID:12411397, PMID:14516795, PMID:14673156, PMID:15070696, PMID:15297429, PMID:15782132, PMID:15914125, PMID:15919668, PMID:16183647, PMID:16391472, PMID:16537399, PMID:16962100, PMID:17616671, PMID:17728140, PMID:17908691, PMID:18021293, PMID:18495876, PMID:18622747, PMID:19246562, PMID:19567381, PMID:19625624, PMID:19810018, PMID:19922502, PMID:20169165, PMID:20574048, PMID:20682991, PMID:20880397, PMID:20936651, PMID:21036700, PMID:21168265, PMID:21321189, PMID:21357504, PMID:21544240, PMID:21858812, PMID:21898527, PMID:21933187, PMID:21984483, PMID:22215663, PMID:22574221, PMID:22863860, PMID:22869613, PMID:23111315, PMID:23255002, PMID:24299490, PMID:24304514, PMID:24375594, PMID:25307878, PMID:25663935, PMID:25758096, PMID:25884947, PMID:25940091, PMID:26282490, PMID:26369790, PMID:26506538, PMID:26621329, PMID:27579538, PMID:27796870, PMID:28984034, PMID:30236763, PMID:30555576, PMID:30661989, PMID:31051157, PMID:31645432, PMID:31676321, PMID:32044396 NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
JBrowse link
G Rps6kb2 ribosomal protein S6 kinase B2 multiple interactions
decreases activity
ISO MTOR protein inhibits the reaction [Sirolimus results in decreased activity of RPS6KB2 protein]; Sirolimus inhibits the reaction [Phosphatidic Acids results in increased activity of RPS6KB2 protein] CTD PMID:12087098 NCBI chr 1:219,406,201...219,412,888
Ensembl chr 1:219,406,202...219,412,888
JBrowse link
G Rptor regulatory associated protein of MTOR, complex 1 multiple interactions ISO [Sirolimus inhibits the reaction [MTOR protein binds to RPTOR protein]] which results in increased expression of MAP1LC3A protein alternative form; [Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein]] which results in increased activity of AR protein; RPTOR protein inhibits the reaction [Sirolimus results in increased activity of AR protein]; Sirolimus inhibits the reaction [[MTOR protein binds to RAPTOR protein] which binds to LARP1 protein]; Sirolimus inhibits the reaction [Orotic Acid results in decreased phosphorylation of RPTOR protein]; Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein binds to MLST8 protein]; Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein] CTD PMID:18776922, PMID:19505958, PMID:21742779, PMID:22863860, PMID:25940091 NCBI chr10:108,750,620...109,058,691
Ensembl chr10:108,750,620...109,058,691
JBrowse link
G Rrad RRAD, Ras related glycolysis inhibitor and calcium channel regulator multiple interactions ISO Sirolimus promotes the reaction [TP73 protein binds to RRAD promoter] CTD PMID:21245298 NCBI chr19:561,696...564,929
Ensembl chr19:561,727...564,930
JBrowse link
G Rtn4 reticulon 4 multiple interactions EXP Sirolimus inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of RTN4 protein] CTD PMID:26648565 NCBI chr14:114,126,931...114,174,459
Ensembl chr14:114,126,943...114,174,458
JBrowse link
G Rtn4r reticulon 4 receptor multiple interactions EXP Sirolimus inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of RTN4R protein] CTD PMID:26648565 NCBI chr11:86,992,665...87,017,091
Ensembl chr11:86,992,399...87,017,115
JBrowse link
G Runx2 RUNX family transcription factor 2 multiple interactions ISO Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA] CTD PMID:23111315 NCBI chr 9:18,564,743...18,773,092
Ensembl chr 9:18,564,927...18,773,092
JBrowse link
G S100a4 S100 calcium-binding protein A4 decreases expression EXP Sirolimus results in decreased expression of S100A4 mRNA CTD PMID:21865292 NCBI chr 2:189,997,278...189,999,587
Ensembl chr 2:189,997,129...189,999,604
JBrowse link
G S100g S100 calcium binding protein G increases expression EXP Sirolimus results in increased expression of S100G mRNA CTD PMID:21865292 NCBI chr  X:33,442,820...33,445,714
Ensembl chr  X:33,443,186...33,445,709
JBrowse link
G S1pr1 sphingosine-1-phosphate receptor 1 increases expression ISO Sirolimus results in increased expression of S1PR1 mRNA CTD PMID:24356939 NCBI chr 2:218,654,406...218,658,761
Ensembl chr 2:218,654,554...218,658,761
JBrowse link
G Scarb2 scavenger receptor class B, member 2 decreases expression ISO Sirolimus results in decreased expression of SCARB2 mRNA CTD PMID:17016853 NCBI chr14:17,064,173...17,115,620
Ensembl chr14:17,064,353...17,115,963
JBrowse link
G Scd stearoyl-CoA desaturase multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in decreased expression of SCD mRNA] CTD PMID:21245298 NCBI chr 1:264,159,966...264,173,061
Ensembl chr 1:264,160,129...264,172,729
JBrowse link
G Sema3a semaphorin 3A multiple interactions ISO
EXP
Sirolimus inhibits the reaction [chromium hexavalent ion results in increased expression of SEMA3A protein] CTD PMID:30236763 NCBI chr 4:18,170,375...18,545,190
Ensembl chr 4:18,178,656...18,396,035
JBrowse link
G Sema3c semaphorin 3C multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of SEMA3C mRNA] CTD PMID:21245298 NCBI chr 4:14,318,276...14,490,438
Ensembl chr 4:14,318,274...14,490,446
JBrowse link
G Serpina1 serpin family A member 1 affects localization ISO Sirolimus affects the localization of SERPINA1 protein CTD PMID:20511674 NCBI chr 6:127,610,241...127,632,265
Ensembl chr 6:127,610,243...127,632,265
JBrowse link
G Serpina3n serine (or cysteine) peptidase inhibitor, clade A, member 3N increases expression EXP Sirolimus results in increased expression of SERPINA3N mRNA CTD PMID:21865292 NCBI chr 6:128,073,344...128,080,878
Ensembl chr 6:127,941,526...128,080,889
JBrowse link
G Serpine1 serpin family E member 1 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in decreased expression of SERPINE1 mRNA]
Sirolimus inhibits the reaction [Ethylene Chlorohydrin promotes the reaction [Lipopolysaccharides results in increased expression of SERPINE1 mRNA]]
CTD PMID:21245298, PMID:31499194 NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
JBrowse link
G Sesn2 sestrin 2 multiple interactions ISO [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of SESN2 mRNA CTD PMID:25307878 NCBI chr 5:150,684,891...150,703,846
Ensembl chr 5:150,684,133...150,704,117
JBrowse link
G Shisa2 shisa family member 2 increases expression ISO Sirolimus results in increased expression of SHISA2 mRNA CTD PMID:24356939 NCBI chr15:39,945,095...39,949,393
Ensembl chr15:39,945,095...39,949,393
JBrowse link
G Sirt1 sirtuin 1 multiple interactions
increases response to substance
increases expression
decreases expression
ISO
EXP
[(+)-JQ1 compound co-treated with Sirolimus] results in decreased expression of SIRT1 protein; Aspirin inhibits the reaction [Sirolimus results in decreased expression of SIRT1 protein]; cilostazol inhibits the reaction [Sirolimus results in decreased expression of SIRT1 protein]
SIRT1 protein results in increased susceptibility to Sirolimus
Sirolimus results in increased expression of SIRT1 protein
Sirolimus inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]]
CTD PMID:19520256, PMID:22561310, PMID:25307878 NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
JBrowse link
G Sirt2 sirtuin 2 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of SIRT2 mRNA] CTD PMID:21245298 NCBI chr 1:86,948,866...86,971,954
Ensembl chr 1:86,948,918...86,971,952
JBrowse link
G Skp2 S-phase kinase associated protein 2 decreases expression ISO Sirolimus results in decreased expression of SKP2 protein CTD PMID:21092744 NCBI chr 2:58,506,146...58,534,211
Ensembl chr 2:58,506,151...58,534,211
JBrowse link
G Slc12a1 solute carrier family 12 member 1 multiple interactions
decreases expression
EXP rosiglitazone inhibits the reaction [Sirolimus results in decreased expression of SLC12A1 protein] CTD PMID:19656910 NCBI chr 3:117,421,531...117,498,372
Ensembl chr 3:117,421,604...117,498,367
JBrowse link
G Slc12a3 solute carrier family 12 member 3 increases expression EXP Sirolimus results in increased expression of SLC12A3 mRNA CTD PMID:21865292 NCBI chr19:11,106,033...11,144,674
Ensembl chr19:11,106,033...11,144,641
JBrowse link
G Slc15a1 solute carrier family 15 member 1 multiple interactions ISO Sirolimus inhibits the reaction [rosiglitazone results in increased expression of and results in increased activity of SLC15A1 protein] CTD PMID:22108913 NCBI chr15:106,800,081...106,844,668
Ensembl chr15:106,800,081...106,844,426
JBrowse link
G Slc16a1 solute carrier family 16 member 1 decreases expression EXP Sirolimus results in decreased expression of SLC16A1 mRNA CTD PMID:21865292 NCBI chr 2:207,108,552...207,129,352
Ensembl chr 2:207,108,552...207,128,554
JBrowse link
G Slc22a13 solute carrier family 22 member 13 decreases expression EXP Sirolimus results in decreased expression of SLC22A13 mRNA CTD PMID:21865292 NCBI chr 8:127,885,268...127,900,829
Ensembl chr 8:127,885,268...127,900,463
JBrowse link
G Slc5a1 solute carrier family 5 member 1 decreases expression EXP Sirolimus results in decreased expression of SLC5A1 mRNA CTD PMID:21865292 NCBI chr14:82,910,448...82,975,303
Ensembl chr14:82,909,981...82,975,263
JBrowse link
G Slc7a12 solute carrier family 7 (cationic amino acid transporter, y+ system), member 12 increases expression EXP Sirolimus results in increased expression of SLC7A12 mRNA CTD PMID:21865292 NCBI chr 2:88,559,677...88,660,449
Ensembl chr 2:88,559,702...88,660,449
JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 increases expression EXP Sirolimus results in increased expression of SLCO1A4 mRNA CTD PMID:11589784 NCBI chr 4:175,969,549...176,026,227
Ensembl chr 4:175,969,549...176,026,163
JBrowse link
G Smim14 small integral membrane protein 14 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of SMIM14 mRNA] CTD PMID:21245298 NCBI chr14:44,413,636...44,460,044
Ensembl chr14:44,413,636...44,457,239
JBrowse link
G Snai1 snail family transcriptional repressor 1 multiple interactions
increases expression
ISO
EXP
Sirolimus inhibits the reaction [sodium arsenite results in increased expression of SNAI1 mRNA]
NFE2L2 protein promotes the reaction [Sirolimus inhibits the reaction [Paraquat results in increased expression of SNAI1 protein]]; Sirolimus inhibits the reaction [Paraquat results in increased expression of SNAI1 mRNA]; Sirolimus inhibits the reaction [Paraquat results in increased expression of SNAI1 protein]; Sirolimus promotes the reaction [Dibutyl Phthalate results in increased expression of SNAI1 mRNA]
Sirolimus results in increased expression of SNAI1 protein
CTD PMID:28624451, PMID:28888487, PMID:30053495 NCBI chr 3:164,274,710...164,279,199
Ensembl chr 3:164,274,710...164,279,378
JBrowse link
G Snca synuclein alpha multiple interactions ISO Sirolimus inhibits the reaction [Paraquat results in increased expression of SNCA protein] CTD PMID:32306690 NCBI chr 4:90,782,412...90,883,236
Ensembl chr 4:90,782,374...90,882,285
JBrowse link
G Sod2 superoxide dismutase 2 decreases expression ISO Sirolimus results in decreased expression of SOD2 protein CTD PMID:30905858 NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
JBrowse link
G Sox2 SRY-box transcription factor 2 increases expression ISO Sirolimus results in increased expression of SOX2 mRNA CTD PMID:21681844 NCBI chr 2:121,165,137...121,167,545
Ensembl chr 2:121,165,137...121,167,545
JBrowse link
G Spp1 secreted phosphoprotein 1 multiple interactions ISO Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased expression of SPP1 protein] CTD PMID:31051157 NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions
increases degradation
increases expression
decreases expression
ISO
EXP
bafilomycin A1 inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; CD38 mutant form inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; Niacinamide inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; Resveratrol inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of SQSTM1 protein]
Sirolimus results in increased degradation of SQSTM1 protein
Sirolimus results in increased expression of SQSTM1 protein
[Sirolimus co-treated with TNF protein] results in decreased expression of SQSTM1 protein; Resveratrol inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of SQSTM1 protein]; Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased expression of SQSTM1 protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of SQSTM1 protein]; Sirolimus promotes the reaction [tris(1,3-dichloro-2-propyl)phosphate results in increased degradation of SQSTM1 protein]
[Sirolimus co-treated with cadmium acetate] results in decreased expression of SQSTM1 mRNA; Sirolimus inhibits the reaction [Epirubicin results in increased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [manganese chloride results in increased expression of SQSTM1 protein]; Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased expression of SQSTM1 protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of SQSTM1 protein]; Sirolimus promotes the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in increased expression of SQSTM1 protein]]
CTD PMID:19773376, PMID:24238063, PMID:24304514, PMID:25884947, PMID:28025121, PMID:29128638, PMID:29218509, PMID:29222055, PMID:29505745, PMID:29518472, PMID:29870746, PMID:30338810, PMID:31676321, PMID:32430275, PMID:32645460 NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
JBrowse link
G Src SRC proto-oncogene, non-receptor tyrosine kinase multiple interactions ISO [Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein] which results in increased phosphorylation of EGFR protein; [Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein] which results in increased phosphorylation of MAPK1 protein; [Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein] which results in increased phosphorylation of MAPK3 protein; Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in decreased phosphorylation of SRC protein]; Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein CTD PMID:19151764, PMID:31499194 NCBI chr 3:153,547,807...153,595,643
Ensembl chr 3:153,580,861...153,595,642
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 decreases expression ISO Sirolimus results in decreased expression of SREBF1 mRNA CTD PMID:15358118 NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
JBrowse link
G Srr serine racemase multiple interactions ISO Sirolimus inhibits the reaction [methyllycaconitine results in increased expression of SRR protein] CTD PMID:24012499 NCBI chr10:61,756,138...61,772,327
Ensembl chr10:61,756,138...61,772,293
JBrowse link
G Stard10 StAR-related lipid transfer domain containing 10 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of STARD10 mRNA] CTD PMID:21245298 NCBI chr 1:166,428,780...166,458,413
Ensembl chr 1:166,428,761...166,457,509
JBrowse link
G Stat3 signal transducer and activator of transcription 3 decreases phosphorylation
multiple interactions
ISO
EXP
Sirolimus results in decreased phosphorylation of STAT3 protein
Sirolimus inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of STAT3 protein]
Sirolimus inhibits the reaction [IFNG protein results in decreased phosphorylation of STAT3 protein]
CTD PMID:16391472, PMID:16427044, PMID:20038814, PMID:26648565 NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
JBrowse link
G Sts steroid sulfatase multiple interactions ISO Sirolimus inhibits the reaction [Tretinoin results in increased activity of STS protein] CTD PMID:16178010 NCBI chr  X:45,420,418...45,428,748
Ensembl chr  X:45,420,596...45,428,750
JBrowse link
G Suv39h1 suppressor of variegation 3-9 homolog 1 multiple interactions ISO [TNF protein co-treated with Sirolimus co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of SUV39H1 protein; [TNF protein co-treated with Sirolimus] results in decreased expression of SUV39H1 protein CTD PMID:31676321 NCBI chr  X:146,532,002...146,533,538 JBrowse link
G Syt1 synaptotagmin 1 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of SYT1 mRNA] CTD PMID:21245298 NCBI chr 7:50,084,063...50,638,996
Ensembl chr 7:50,084,060...50,638,798
JBrowse link
G Taf12 TATA-box binding protein associated factor 12 decreases expression ISO Sirolimus results in decreased expression of TAF12 mRNA CTD PMID:11355896 NCBI chr 5:150,459,701...150,476,521
Ensembl chr 5:150,459,713...150,475,186
JBrowse link
G Tal1 TAL bHLH transcription factor 1, erythroid differentiation factor multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein affects the activity of TAL1 protein] CTD PMID:21245298 NCBI chr 5:133,864,401...133,878,604
Ensembl chr 5:133,864,798...133,878,830
JBrowse link
G Tardbp TAR DNA binding protein multiple interactions ISO Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of TARDBP protein] CTD PMID:25884947 NCBI chr 5:165,432,089...165,442,232
Ensembl chr 5:165,432,095...165,442,048
JBrowse link
G Tars1 threonyl-tRNA synthetase 1 decreases expression ISO Sirolimus results in decreased expression of TARS mRNA CTD PMID:11355896 NCBI chr 2:61,394,632...61,414,115
Ensembl chr 2:61,394,770...61,414,102
JBrowse link
G Tax1bp1 Tax1 binding protein 1 increases expression ISO Sirolimus results in increased expression of TAX1BP1 mRNA CTD PMID:11355896 NCBI chr 4:82,776,720...82,832,586
Ensembl chr 4:82,776,746...82,833,773
JBrowse link
G Tcf19 transcription factor 19 multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of TCF19 mRNA CTD PMID:19016759 NCBI chr20:3,740,454...3,746,964
Ensembl chr20:3,744,395...3,746,964
JBrowse link
G Tead1 TEA domain transcription factor 1 multiple interactions ISO Sirolimus promotes the reaction [TP73 protein affects the activity of TEAD1 protein] CTD PMID:21245298 NCBI chr 1:177,495,500...177,714,795
Ensembl chr 1:177,495,782...177,707,061
JBrowse link
G Tert telomerase reverse transcriptase decreases expression ISO Sirolimus results in decreased expression of TERT mRNA; Sirolimus results in decreased expression of TERT protein CTD PMID:12939469, PMID:16455087, PMID:17996122, PMID:20863555 NCBI chr 1:32,250,876...32,275,330
Ensembl chr 1:32,251,714...32,272,476
JBrowse link
G Tfeb transcription factor EB affects localization ISO Sirolimus affects the localization of TFEB protein CTD PMID:28366621 NCBI chr 9:15,208,141...15,264,101
Ensembl chr 9:15,207,822...15,214,596
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions
decreases expression
increases response to substance
ISO
EXP
[Sirolimus binds to FKBP1A protein] which results in increased activity of TGFB1 protein; [Sirolimus co-treated with TGFB1 protein] affects the localization of CDK2 protein; [Sirolimus co-treated with TGFB1 protein] affects the localization of CDKN1B protein; [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1A protein binds to CDK2 protein]; [Sirolimus co-treated with TGFB1 protein] results in decreased phosphorylation of RB1 protein; [Sirolimus co-treated with TGFB1 protein] results in increased expression of CDKN1A protein; [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL1 protein] which binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL2 protein] which binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1A protein]; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein]; [TGFB1 protein co-treated with Sirolimus] results in decreased activity of CDK2 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased expression of E2F1 mRNA; [TGFB1 protein co-treated with Sirolimus] results in decreased expression of E2F1 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of CDK2 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of RB1 protein; [TGFB1 protein co-treated with Sirolimus] results in increased expression of CDKN1A protein; [TGFB1 protein modified form co-treated with Sirolimus] results in decreased expression of IL6 mRNA; [TGFB1 protein modified form co-treated with Sirolimus] results in decreased expression of IL6 protein; [TGFB1 protein modified form co-treated with Sirolimus] results in increased expression of FOXP3 mRNA; [TGFB1 protein modified form co-treated with Sirolimus] results in increased expression of FOXP3 protein
Sirolimus results in decreased expression of TGFB1 mRNA
Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 mRNA]; Sirolimus inhibits the reaction [Doxorubicin results in increased expression of TGFB1 protein]; Sirolimus inhibits the reaction [Thioacetamide results in increased expression of TGFB1 mRNA]
TGFB1 protein results in increased susceptibility to Sirolimus
[Sirolimus co-treated with TGFB1 protein] affects the localization of CDK2 protein; [Sirolimus co-treated with TGFB1 protein] affects the localization of CDKN1B protein; [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1B protein binds to CDK2 protein]; [Sirolimus co-treated with TGFB1 protein] results in decreased activity of CDK2 protein; [Sirolimus co-treated with TGFB1 protein] results in decreased phosphorylation of RB1 protein; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein]; [TGFB1 protein co-treated with Sirolimus] results in decreased expression of E2F1 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased expression of MYBL2 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of RB1 protein; Sirolimus inhibits the reaction [[Cadmium Chloride co-treated with TGFB1 protein] results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [[Cadmium Chloride co-treated with TGFB1 protein] results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [[Cadmium Chloride co-treated with TGFB1 protein] results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [TGFB1 protein inhibits the reaction [Cadmium Chloride results in increased expression of CASP3 protein]]; Sirolimus inhibits the reaction [TGFB1 protein inhibits the reaction [Cadmium Chloride results in increased expression of CASP8 protein]]; Sirolimus inhibits the reaction [TGFB1 protein inhibits the reaction [Cadmium Chloride results in increased expression of CASP9 protein]]
CTD PMID:10535884, PMID:12417722, PMID:14979923, PMID:17050028, PMID:17550925, PMID:17700525, PMID:20844194, PMID:24971338, PMID:28342888 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Tgfbr3 transforming growth factor beta receptor 3 increases expression ISO Sirolimus results in increased expression of TGFBR3 mRNA CTD PMID:11355896 NCBI chr14:3,506,416...3,680,508
Ensembl chr14:3,506,339...3,682,545
JBrowse link
G Tgm2 transglutaminase 2 decreases expression ISO Sirolimus results in decreased expression of TGM2 mRNA CTD PMID:11355896 NCBI chr 3:154,597,165...154,627,257
Ensembl chr 3:154,597,168...154,627,257
JBrowse link
G Timeless timeless circadian regulator multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of TIMELESS mRNA CTD PMID:19016759 NCBI chr 7:2,643,288...2,667,329
Ensembl chr 7:2,643,288...2,667,628
JBrowse link
G Timp3 TIMP metallopeptidase inhibitor 3 decreases expression ISO Sirolimus results in decreased expression of TIMP3 mRNA; Sirolimus results in decreased expression of TIMP3 protein CTD PMID:21742783 NCBI chr 7:23,543,125...23,594,170
Ensembl chr 7:23,544,215...23,594,133
JBrowse link
G Tmem14c transmembrane protein 14C multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in increased expression of TMEM14C mRNA] CTD PMID:21245298 NCBI chr17:21,571,510...21,577,651
Ensembl chr17:21,571,518...21,577,631
JBrowse link
G Tnf tumor necrosis factor multiple interactions
decreases expression
decreases secretion
increases expression
ISO
EXP
[Sirolimus co-treated with TNF protein] results in decreased expression of SQSTM1 protein; [Sirolimus co-treated with TNF protein] results in increased expression of ATG5 mRNA; [Sirolimus co-treated with TNF protein] results in increased expression of ATG7 mRNA; [Sirolimus co-treated with TNF protein] results in increased expression of BECN1 protein; [TNF protein co-treated with Sirolimus co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of SUV39H1 protein; [TNF protein co-treated with Sirolimus] results in decreased expression of SUV39H1 protein; Sirolimus inhibits the reaction [TNF protein results in decreased expression of PTEN protein]; Sirolimus inhibits the reaction [TNF protein results in decreased expression of TSC2 mRNA]; Sirolimus inhibits the reaction [TNF protein results in decreased expression of TSC2 protein]; Sirolimus inhibits the reaction [TNF protein results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus promotes the reaction [TNF protein results in increased expression of and results in increased lipidation of MAP1LC3B protein]; Sirolimus promotes the reaction [TNF protein results in increased expression of F3 protein]
Sirolimus inhibits the reaction [[Zearalenone co-treated with Lipopolysaccharides] results in increased expression of TNF protein]; Sirolimus inhibits the reaction [Hydrogen Peroxide results in increased secretion of TNF protein]; Sirolimus inhibits the reaction [Isoproterenol results in increased expression of TNF mRNA]; Sirolimus inhibits the reaction [Isoproterenol results in increased expression of TNF protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of ACADL mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of ACADM mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of CPT1B mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of CPT2 mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARA mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARA protein]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARGC1A mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARGC1A protein]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL1B mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL1B protein]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL2 mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL2 protein]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of MYH7 mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of NPPA mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of NPPB mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of TNF mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of TNF protein]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased phosphorylation of MTOR protein]]
Sirolimus results in decreased expression of TNF mRNA
Sirolimus results in decreased secretion of TNF protein
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6 protein]
Sirolimus results in increased expression of TNF
CTD PMID:12531798, PMID:14502240, PMID:16314788, PMID:19567381, PMID:19810018, PMID:21600178, PMID:22069489, PMID:22363816, PMID:24971338, PMID:25045214, PMID:31332898, PMID:31586597, PMID:31676321 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tnfsf11 TNF superfamily member 11 multiple interactions ISO Sirolimus inhibits the reaction [TNFSF11 protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [TNFSF11 protein results in increased phosphorylation of RPS6 protein] CTD PMID:14502240 NCBI chr15:60,482,527...60,512,704
Ensembl chr15:60,482,527...60,512,704
JBrowse link
G Tp53 tumor protein p53 multiple interactions
increases expression
decreases phosphorylation
ISO
EXP
[Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of TP53 protein; Sirolimus inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein]; Sirolimus promotes the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein]]; Sirolimus promotes the reaction [TP53 protein results in increased expression of BBC3 protein]
Sirolimus results in increased expression of TP53 mRNA
Sirolimus results in decreased phosphorylation of TP53 protein
CTD PMID:11602639, PMID:19560264, PMID:24971338, PMID:30555576 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Tp63 tumor protein p63 decreases expression ISO Sirolimus results in decreased expression of TP63 protein
Sirolimus results in decreased expression of TRP63 protein
CTD PMID:20038814 NCBI chr11:78,234,853...78,456,559
Ensembl chr11:78,234,800...78,456,501
JBrowse link
G Tp73 tumor protein p73 multiple interactions
increases expression
ISO [[Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein] which results in increased expression of BBC3 protein; [[Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein] which results in increased expression of PMAIP1 protein; [Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein; Sirolimus inhibits the reaction [TP73 protein affects the activity of HEN1 protein]; Sirolimus inhibits the reaction [TP73 protein affects the activity of HOXA9 protein]; Sirolimus inhibits the reaction [TP73 protein affects the activity of TAL1 protein]; Sirolimus inhibits the reaction [TP73 protein affects the activity of ZIC2 protein]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of ACER2 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of JMY mRNA]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of MIR181A2 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of NR1H4 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of RPL7P26 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of SCD mRNA]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of SERPINE1 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of YPEL1 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of AOPEP mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of BTBD11 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of CAV3 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of CCNG2 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of CHRNB3 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of DEPTOR mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of FAXDC2 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of FBXO32 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of FGF7 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of FOLR1 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of FTL mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of ING4 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of MBNL2 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of MTURN mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of MYLK mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of MYOF mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of NMU mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of OXA1L mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of POLR1H mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of SEMA3C mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of SIRT2 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of SMIM14 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of STARD10 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of SYT1 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of TMEM14C mRNA]; Sirolimus promotes the reaction [TP73 protein affects the activity of GCM2 protein]; Sirolimus promotes the reaction [TP73 protein affects the activity of PAX8 protein]; Sirolimus promotes the reaction [TP73 protein affects the activity of REST protein]; Sirolimus promotes the reaction [TP73 protein affects the activity of TEAD1 protein]; Sirolimus promotes the reaction [TP73 protein binds to MDM2 promoter]; Sirolimus promotes the reaction [TP73 protein binds to RPS27L promoter]; Sirolimus promotes the reaction [TP73 protein binds to RRAD promoter]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR151 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR190A mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR29C mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR324 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR379 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR433 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR503 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR508 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR650 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR654 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR758 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR760 mRNA]; TP73 protein results in increased susceptibility to [Sirolimus co-treated with Cisplatin]
Sirolimus results in increased expression of TP73 protein
CTD PMID:20686837, PMID:21245298 NCBI chr 5:171,355,876...171,415,354
Ensembl chr 5:171,355,876...171,415,354
JBrowse link
G Tpp2 tripeptidyl peptidase 2 multiple interactions ISO Sirolimus promotes the reaction [Etoposide affects the localization of TPP2 protein] CTD PMID:20643100 NCBI chr 9:50,664,048...50,744,803
NCBI chr 9:50,578,868...50,628,943
Ensembl chr 9:50,581,234...50,744,803
JBrowse link
G Trib3 tribbles pseudokinase 3 multiple interactions ISO [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of TRIB3 mRNA CTD PMID:25307878 NCBI chr 3:147,814,056...147,819,650
Ensembl chr 3:147,813,473...147,819,571
JBrowse link
G Trpm6 transient receptor potential cation channel, subfamily M, member 6 multiple interactions
increases expression
EXP rosiglitazone inhibits the reaction [Sirolimus results in increased expression of TRPM6 protein] CTD PMID:19656910 NCBI chr 1:234,478,908...234,631,264
Ensembl chr 1:234,479,289...234,596,971
JBrowse link
G Tsc1 TSC complex subunit 1 multiple interactions ISO Sirolimus inhibits the reaction [TSC1 gene mutant form results in decreased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [TSC1 gene mutant form results in decreased phosphorylation of GSK3B protein]; Sirolimus inhibits the reaction [TSC1 gene mutant form results in increased phosphorylation of RPS6KB1 protein] CTD PMID:18495876 NCBI chr 3:7,219,955...7,269,063
Ensembl chr 3:7,237,192...7,265,145
JBrowse link
G Tsc2 TSC complex subunit 2 multiple interactions EXP
ISO
Sirolimus inhibits the reaction [Resveratrol inhibits the reaction [TSC2 protein results in decreased phosphorylation of RPS6KB1 protein]]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased expression of DDIT3 protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased expression of ERO1A mRNA]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased expression of HMOX1 protein]; TSC2 protein inhibits the reaction [[Sirolimus co-treated with Resveratrol] results in increased cleavage of PARP1 protein]
[Resveratrol co-treated with Sirolimus] inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of EIF4B protein]; [Sirolimus co-treated with Resveratrol] inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of RPS6KB1 protein]; [Sirolimus co-treated with Resveratrol] promotes the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1 protein]; Resveratrol inhibits the reaction [Sirolimus inhibits the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1S1 protein]]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1S1 protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of EIF4B protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of RPS6KB1 protein]; TSC2 gene mutant form promotes the reaction [[Sirolimus co-treated with Resveratrol] results in increased stability of PDCD4 protein]
Sirolimus inhibits the reaction [TNF protein results in decreased expression of TSC2 mRNA]; Sirolimus inhibits the reaction [TNF protein results in decreased expression of TSC2 protein]; TSC2 gene mutant form promotes the reaction [[Resveratrol co-treated with Sirolimus] results in decreased phosphorylation of RPS6 protein]; TSC2 gene mutant form promotes the reaction [Sirolimus results in decreased phosphorylation of RPS6 protein]
CTD PMID:19420259, PMID:24304514, PMID:31676321 NCBI chr10:13,962,006...13,996,684
Ensembl chr10:13,961,947...13,996,584
JBrowse link
G Ttk Ttk protein kinase multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of TTK mRNA CTD PMID:19016759 NCBI chr 8:91,368,065...91,405,995
Ensembl chr 8:91,368,111...91,405,993
JBrowse link
G Tyms thymidylate synthetase decreases expression ISO Sirolimus results in decreased expression of TYMS; Sirolimus results in decreased expression of TYMS mRNA CTD PMID:19764996, PMID:20682991 NCBI chr 9:121,918,875...121,931,564
Ensembl chr 9:121,918,947...121,931,564
JBrowse link
G Ulk1 unc-51 like autophagy activating kinase 1 multiple interactions EXP
ISO
Sirolimus affects the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide affects the reaction [Glucose affects the phosphorylation of ULK1 protein]]; Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased expression of ULK1 protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of ULK1 protein] CTD PMID:29128638, PMID:29518472 NCBI chr12:51,908,105...51,934,704
Ensembl chr12:51,908,448...51,934,702
JBrowse link
G Uri1 URI1, prefoldin-like chaperone decreases response to substance ISO URI1 results in decreased susceptibility to Sirolimus CTD PMID:21397856 NCBI chr 1:94,346,513...94,404,362
Ensembl chr 1:94,346,514...94,404,211
JBrowse link
G Vasn vasorin decreases expression EXP Sirolimus results in decreased expression of VASN mRNA CTD PMID:17028423 NCBI chr10:11,121,041...11,131,548
Ensembl chr10:11,121,041...11,131,548
JBrowse link
G Vcan versican increases expression EXP Sirolimus results in increased expression of VCAN mRNA CTD PMID:21865292 NCBI chr 2:18,490,102...18,587,340
Ensembl chr 2:18,490,102...18,565,842
JBrowse link
G Vcp valosin-containing protein multiple interactions ISO Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of SQSTM1 protein]
Sirolimus inhibits the reaction [VCP protein mutant form results in decreased expression of MAP1LC3B protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of OPTN protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of RPS6KB1 protein modified form]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of TARDBP protein]
CTD PMID:25884947 NCBI chr 5:58,426,548...58,445,953
Ensembl chr 5:58,426,549...58,445,953
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions
decreases expression
ISO
EXP
[Curcumin analog co-treated with Sirolimus] inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA protein]; Sirolimus inhibits the reaction [4-hydroxyestradiol results in increased expression of VEGFA protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased secretion of VEGFA protein]; Sirolimus inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA mRNA]
[Sirolimus co-treated with Hydrogen Peroxide] results in increased expression of VEGFA mRNA
Sirolimus results in decreased expression of VEGFA protein
Sirolimus results in decreased expression of VEGFA mRNA
CTD PMID:15050414, PMID:15930297, PMID:16682453, PMID:17968710, PMID:20554536, PMID:24971338, PMID:31332898 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link
G Vim vimentin multiple interactions ISO
EXP
Sirolimus inhibits the reaction [sodium arsenite results in increased expression of VIM protein]
NFE2L2 protein promotes the reaction [Sirolimus inhibits the reaction [Paraquat results in increased expression of VIM protein]]; Sirolimus inhibits the reaction [Paraquat results in increased expression of VIM mRNA]; Sirolimus inhibits the reaction [Paraquat results in increased expression of VIM protein]
CTD PMID:28624451, PMID:28888487 NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
JBrowse link
G Wt1 WT1 transcription factor decreases expression ISO Sirolimus results in decreased expression of WT1 mRNA; Sirolimus results in decreased expression of WT1 protein; Sirolimus results in decreased expression of WT1 protein mutant form CTD PMID:15782132, PMID:18927120 NCBI chr 3:95,133,221...95,180,574
Ensembl chr 3:95,133,713...95,180,564
JBrowse link
G Xbp1 X-box binding protein 1 multiple interactions ISO Sirolimus inhibits the reaction [arsenite results in increased splicing of XBP1 mRNA] CTD PMID:22215663 NCBI chr14:85,753,736...85,758,820
Ensembl chr14:85,753,760...85,758,145
JBrowse link
G Xiap X-linked inhibitor of apoptosis multiple interactions ISO Sirolimus promotes the reaction [Cisplatin results in decreased expression of XIAP protein] CTD PMID:18058806 NCBI chr  X:128,409,425...128,455,786
Ensembl chr  X:128,409,472...128,453,000
JBrowse link
G Ypel1 yippee-like 1 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein results in decreased expression of YPEL1 mRNA] CTD PMID:21245298 NCBI chr11:88,171,401...88,186,000
Ensembl chr11:88,173,890...88,180,542
JBrowse link
G Zfp628 zinc finger protein 628 decreases expression ISO Sirolimus results in decreased expression of ZNF628 mRNA CTD PMID:24356939 NCBI chr 1:72,465,403...72,474,442
Ensembl chr 1:72,465,341...72,468,738
JBrowse link
G Zic2 Zic family member 2 multiple interactions ISO Sirolimus inhibits the reaction [TP73 protein affects the activity of ZIC2 protein] CTD PMID:21245298 NCBI chr15:108,908,366...108,913,812
Ensembl chr15:108,908,607...108,912,737
JBrowse link
G Zwint ZW10 interacting kinetochore protein multiple interactions ISO [fulvestrant co-treated with Sirolimus] results in decreased expression of ZWINT mRNA CTD PMID:19016759 NCBI chr20:17,075,781...17,091,715
Ensembl chr20:17,075,771...17,091,766
JBrowse link
everolimus term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 decreases activity ISO Everolimus results in decreased activity of ABCB11 protein CTD PMID:23956101 NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A affects stability
affects response to substance
multiple interactions
ISO ABCB1A protein affects the stability of Everolimus
ABCB1 polymorphism affects the susceptibility to Everolimus
bis(4-nitrophenyl)phosphate inhibits the reaction [ABCB1A protein affects the stability of Everolimus]; Everolimus inhibits the reaction [ABCB1A protein affects the metabolism of irinotecan]
CTD PMID:24727322, PMID:27169792 NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Abcb1b ATP-binding cassette, subfamily B (MDR/TAP), member 1B affects stability
multiple interactions
ISO ABCB1B protein affects the stability of Everolimus
bis(4-nitrophenyl)phosphate inhibits the reaction [ABCB1B protein affects the stability of Everolimus]; Everolimus inhibits the reaction [ABCB1B protein affects the metabolism of irinotecan]
CTD PMID:24727322 NCBI chr 4:22,225,123...22,307,577
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 affects stability
multiple interactions
ISO ABCG2 protein affects the stability of Everolimus
bis(4-nitrophenyl)phosphate inhibits the reaction [ABCG2 protein affects the stability of Everolimus]; Everolimus inhibits the reaction [ABCG2 protein affects the metabolism of irinotecan]
CTD PMID:24727322 NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
JBrowse link
G Akt1 AKT serine/threonine kinase 1 increases phosphorylation
decreases phosphorylation
ISO Everolimus results in increased phosphorylation of AKT1 protein
Everolimus results in decreased phosphorylation of AKT1 protein
CTD PMID:16033851, PMID:22885370, PMID:23300809, PMID:28711525 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases expression
multiple interactions
ISO Everolimus results in decreased expression of BIRC5 protein
Everolimus promotes the reaction [platycodin D results in decreased expression of BIRC5 protein]; navitoclax promotes the reaction [Everolimus results in decreased expression of BIRC5 protein]; platycodin D promotes the reaction [Everolimus results in decreased expression of BIRC5 protein]
CTD PMID:21601561, PMID:28711525, PMID:28947240 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
JBrowse link
G Brd4 bromodomain containing 4 multiple interactions ISO [MYC protein results in decreased susceptibility to Everolimus] promotes the reaction [BRD4 protein binds to MYC gene] CTD PMID:25537515 NCBI chr 7:14,222,101...14,303,055
Ensembl chr 7:14,222,101...14,303,055
JBrowse link
G Casp3 caspase 3 increases cleavage ISO Everolimus results in increased cleavage of CASP3 protein CTD PMID:15940265 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Ccna2 cyclin A2 decreases expression ISO Everolimus results in decreased expression of CCNA2 protein CTD PMID:16856892 NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
JBrowse link
G Ccnd1 cyclin D1 decreases expression
multiple interactions
ISO Everolimus results in decreased expression of CCND1 protein
[letrozole co-treated with Everolimus] results in decreased expression of CCND1 protein
CTD PMID:16033851 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Ccnd2 cyclin D2 multiple interactions
decreases expression
ISO [letrozole co-treated with Everolimus] results in decreased expression of CCND2 protein
Everolimus results in decreased expression of CCND2 protein
CTD PMID:16033851 NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
JBrowse link
G Ccnd3 cyclin D3 decreases expression ISO Everolimus results in decreased expression of CCND3 protein CTD PMID:16856892 NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943
JBrowse link
G Cdh1 cadherin 1 increases expression ISO Everolimus results in increased expression of CDH1 protein CTD PMID:28258630 NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
JBrowse link
G Ces1d carboxylesterase 1D decreases activity ISO Everolimus results in decreased activity of CES1 protein CTD PMID:24727322 NCBI chr19:15,195,514...15,239,827
Ensembl chr19:15,033,108...15,239,821
JBrowse link
G Ces2h carboxylesterase 2H decreases activity ISO Everolimus results in decreased activity of CES2 protein CTD PMID:24727322 NCBI chr19:37,052,555...37,067,176
Ensembl chr19:37,052,556...37,067,156
JBrowse link
G Egfr epidermal growth factor receptor increases expression
multiple interactions
ISO Everolimus results in increased expression of EGFR mRNA; Everolimus results in increased expression of EGFR protein
platycodin D inhibits the reaction [Everolimus results in increased expression of EGFR protein]
CTD PMID:28711525 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Eif4e eukaryotic translation initiation factor 4E increases phosphorylation
multiple interactions
ISO Everolimus results in increased phosphorylation of EIF4E protein
Everolimus inhibits the reaction [Estradiol results in decreased phosphorylation of EIF4E protein]
CTD PMID:16033851 NCBI chr 2:243,819,616...243,853,987
Ensembl chr 2:243,820,661...243,852,631
JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions
decreases phosphorylation
ISO [letrozole co-treated with Everolimus] results in increased phosphorylation of and results in decreased activity of EIF4EBP1 protein; Everolimus inhibits the reaction [Estradiol results in increased phosphorylation of and results in decreased activity of EIF4EBP1 protein]; Everolimus promotes the reaction [platycodin D results in decreased phosphorylation of EIF4EBP1 protein]; Everolimus results in increased phosphorylation of and results in decreased activity of EIF4EBP1 protein; platycodin D promotes the reaction [Everolimus results in decreased phosphorylation of EIF4EBP1 protein] CTD PMID:16033851, PMID:16856892, PMID:16951235, PMID:21372221, PMID:28711525 NCBI chr16:68,954,860...68,968,248
Ensembl chr16:68,954,875...68,968,248
JBrowse link
G Eif4g1 eukaryotic translation initiation factor 4 gamma, 1 multiple interactions ISO Everolimus inhibits the reaction [Estradiol results in increased phosphorylation of EIF4G1 protein] CTD PMID:16033851 NCBI chr11:83,907,659...83,927,683
Ensembl chr11:83,908,109...83,926,524
JBrowse link
G F3 coagulation factor III, tissue factor multiple interactions ISO Everolimus promotes the reaction [TNF protein results in increased expression of F3 protein] CTD PMID:19567381 NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
JBrowse link
G Igf1r insulin-like growth factor 1 receptor multiple interactions
increases expression
ISO platycodin D inhibits the reaction [Everolimus results in increased expression of IGF1R protein]
Everolimus results in increased expression of IGF1R mRNA; Everolimus results in increased expression of IGF1R protein
CTD PMID:28711525 NCBI chr 1:128,924,921...129,213,816
Ensembl chr 1:128,924,966...129,206,516
JBrowse link
G Itgam integrin subunit alpha M multiple interactions ISO Everolimus promotes the reaction [Tretinoin results in increased expression of ITGAM protein] CTD PMID:29743969 NCBI chr 1:199,495,312...199,545,738
Ensembl chr 1:199,495,298...199,623,960
JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO Everolimus inhibits the reaction [4-cresol results in increased expression of MMP9 protein] CTD PMID:30910523 NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
JBrowse link
G Mtor mechanistic target of rapamycin kinase multiple interactions
decreases activity
ISO
EXP
[Everolimus co-treated with Y 27632] inhibits the reaction [4-cresol results in increased phosphorylation of MTOR protein]; [Letrozole co-treated with Everolimus] inhibits the reaction [Androstenedione affects the activity of MTOR protein]; Everolimus inhibits the reaction [4-cresol results in increased phosphorylation of MTOR protein]; Everolimus inhibits the reaction [Androstenedione affects the activity of MTOR protein]; Everolimus inhibits the reaction [Estradiol affects the activity of MTOR protein]; Everolimus inhibits the reaction [MTOR results in decreased susceptibility to Trabectedin]
Everolimus inhibits the reaction [rhodioloside inhibits the reaction [[cobaltous chloride co-treated with NGF protein] results in decreased phosphorylation of MTOR protein]]
Everolimus results in decreased activity of MTOR; Everolimus results in decreased activity of MTOR protein
CTD PMID:16033851, PMID:20890178, PMID:21622721, PMID:24989011, PMID:30910523 NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions
decreases response to substance
increases expression
ISO [MYC protein results in decreased susceptibility to Everolimus] promotes the reaction [BRD4 protein binds to MYC gene]
Everolimus results in increased expression of MYC protein
CTD PMID:25537515 NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
JBrowse link
G Ngf nerve growth factor multiple interactions EXP Everolimus inhibits the reaction [rhodioloside inhibits the reaction [[cobaltous chloride co-treated with NGF protein] results in decreased phosphorylation of MTOR protein]]; Everolimus inhibits the reaction [rhodioloside inhibits the reaction [[cobaltous chloride co-treated with NGF protein] results in decreased phosphorylation of RPS6KB1 protein]] CTD PMID:24989011 NCBI chr 2:204,886,158...204,939,523
Ensembl chr 2:204,886,202...204,940,453
JBrowse link
G Nos3 nitric oxide synthase 3 multiple interactions
decreases expression
ISO Aspirin inhibits the reaction [Everolimus results in decreased expression of NOS3 protein]; cilostazol inhibits the reaction [Everolimus results in decreased expression of NOS3 protein] CTD PMID:19520256 NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 decreases activity ISO Everolimus results in decreased activity of NR1I3 protein CTD PMID:30203046 NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [navitoclax co-treated with Everolimus] results in increased cleavage of PARP1 protein CTD PMID:28947240 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression EXP Everolimus results in increased expression of PTGS2 mRNA; Everolimus results in increased expression of PTGS2 protein CTD PMID:15937522 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Ptk2 protein tyrosine kinase 2 decreases expression ISO Everolimus results in decreased expression of PTK2 protein modified form CTD PMID:28258630 NCBI chr 7:114,436,419...114,611,317
Ensembl chr 7:114,437,361...114,590,119
JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions
decreases phosphorylation
ISO [letrozole co-treated with Everolimus] results in decreased phosphorylation of and affects the activity of RB1 protein; Everolimus results in decreased phosphorylation of and affects the activity of RB1 protein
Everolimus results in decreased phosphorylation of RB1 protein
CTD PMID:16033851, PMID:16856892 NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
JBrowse link
G Rhoa ras homolog family member A decreases expression
multiple interactions
ISO Everolimus results in decreased expression of RHOA protein
[Everolimus co-treated with Y 27632] inhibits the reaction [4-cresol results in increased expression of RHOA protein]
CTD PMID:28258630, PMID:30910523 NCBI chr 8:117,082,440...117,116,244
Ensembl chr 8:117,106,576...117,116,167
JBrowse link
G Rps6 ribosomal protein S6 multiple interactions
decreases phosphorylation
ISO [letrozole co-treated with Everolimus] results in decreased phosphorylation of RPS6 protein; Everolimus inhibits the reaction [Estradiol results in increased phosphorylation of RPS6 protein]
Everolimus results in decreased phosphorylation of RPS6 protein
CTD PMID:16033851, PMID:21372221, PMID:22885370, PMID:23151917, PMID:23300809, PMID:24386346 NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 multiple interactions EXP
ISO
Everolimus inhibits the reaction [rhodioloside inhibits the reaction [[cobaltous chloride co-treated with NGF protein] results in decreased phosphorylation of RPS6KB1 protein]]
Everolimus inhibits the reaction [Estradiol results in increased phosphorylation of RPS6KB1 protein]; Everolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]
CTD PMID:16033851, PMID:19567381, PMID:24989011 NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
JBrowse link
G Sirt1 sirtuin 1 multiple interactions
decreases expression
ISO Aspirin inhibits the reaction [Everolimus results in decreased expression of SIRT1 protein]; cilostazol inhibits the reaction [Everolimus results in decreased expression of SIRT1 protein] CTD PMID:19520256 NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
JBrowse link
G Src SRC proto-oncogene, non-receptor tyrosine kinase decreases expression ISO Everolimus results in decreased expression of SRC protein modified form CTD PMID:28258630 NCBI chr 3:153,547,807...153,595,643
Ensembl chr 3:153,580,861...153,595,642
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO Everolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]; Everolimus promotes the reaction [TNF protein results in increased expression of F3 protein] CTD PMID:19567381 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Vim vimentin decreases expression ISO Everolimus results in decreased expression of VIM protein CTD PMID:28258630 NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19816
    role 19764
      biological role 19764
        immunomodulator 13696
          immunosuppressive agent 11941
            sirolimus 476
              everolimus 39
              ridaforolimus 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19816
    subatomic particle 19814
      composite particle 19814
        hadron 19814
          baryon 19814
            nucleon 19814
              atomic nucleus 19814
                atom 19814
                  main group element atom 19702
                    p-block element atom 19702
                      carbon group element atom 19608
                        carbon atom 19597
                          organic molecular entity 19597
                            organic group 18537
                              organic divalent group 18530
                                organodiyl group 18530
                                  carbonyl group 18436
                                    carbonyl compound 18436
                                      carboxylic acid 18114
                                        carboacyl group 17372
                                          univalent carboacyl group 17372
                                            carbamoyl group 17158
                                              carboxamide 17158
                                                lactam 8034
                                                  macrolide lactam 770
                                                    sirolimus 476
                                                      everolimus 39
                                                      ridaforolimus 0
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.